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ABSTRACT  
The Mucopolysaccharidoses (MPSs) are a class of lysosomal storage diseases 
characterized by lysosomal accumulation of glycosaminoglycan (GAG). 
Understanding the pathogenesis of the neuropathic forms of MPS and improving 
treatment options for these disorders are major areas of research in the laboratory of 
Dr. Ellinwood. The neuropathic MPSs include MPS I, II, III (A-D), and VII, all of which 
have primary storage of heparan sulfate (HS), and a secondary accumulation of 
GM2 and GM3 gangliosides. Clinically patients with the severe forms of these 
disorders have central nervous system defects. Mucopolysaccharidosis III, also 
known as Sanfilippo syndrome, has four subtypes designated as A-D. These 
subtypes are due to deficiency of four different and distinct lysosomal enzymes. 
Mucopolysaccharidosis type IIIB (MPS IIIB) results from an inherited deficiency of N-
acetyl-α-D-glucosaminidase (Naglu) activity which leads to lysosomal accumulation 
of HS as a primary storage substrate, and secondary accumulation GM2 and GM3 
gangliosides. Mucopolysaccharidosis type IIIC is characterized by deficiency of the 
HSGNAT gene product, a lysosomal membrane enzyme. No treatment exists for 
MPS IIIB, but potential treatments could involve a combination of gene therapy (GT) 
and hematopoietic stem cell therapy (HSCT). To this end we construction a lentiviral 
vector containing hNaglu-cDNA under the control of the hPGK promoter. This vector 
will be used in the future for ex vivo transduction of HSCT to be followed by 
transplantation into lethally irradiated MPS IIIB mice. While work proceeds on 
development of therapy there is still a critical need for a better understanding of the 
disease process in MPS III. Use of mouse models could aid this process very 
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effectively. To this end we used a double knockout (DKO) approach to test a theory 
on an approach to improve treatment of MPS IIIB. This approach had as its goal a 
better understanding of the pathogenesis of MPS IIIB, by targeting, through 
substrate reduction, ganglioside accumulation at the genetic level. This DKO 
approach entailed breeding mice deficient in both Naglu (the causative gene in MPS 
IIIB) and GalNAcT activity. The latter is the enzyme required for synthesis of GM2 
and other complex gangliosides. If the DKO mice showed improvement relative to 
the single KO MPS IIIB this would provide strong proof or principle to move forward 
with assessment of substrate deprivation therapy (SDT) targeting gangliosides, for 
which drugs are available. Contrary to our expectation and to double knockout 
(DKO) studies where GalNAcT was knocked out in combination with other LSDs, our 
DKO mice showed a drastically shortened lifespan (24.5 ± 1.4 weeks, versus 50.5 ± 
0.9 wks (MPS IIIB), and 38.6 ± 1.2wks (GalNAcT)). To confirm that HS storage was 
the primary element resulting in the accelerated disease in our DKO mice, and not a 
locus tightly linked to the Naglu gene in the embryonic cell like used to generate 
these mice, we replicated our study with MPS IIIA mice, and found a virtually 
identical result (27.5 ± 1.8 weeks, versus 53.8 ± 1.6 wks.). All DKO mice showed 
motor signs of hind limb ataxia and hyper-extension, which were not seen in single 
KO or normal mice. At approximately 5 months of age the MPS IIIB DKO showed a 
unique pattern of vacuolization and nerve fiber degeneration in the corpus callosum 
as well as the mild intracytoplasmic vacuolation of neurons and glia typical of MPS 
IIIB affected mice at this age. We analyzed motor performance on a rocking Rotor-
rod beginning at 3 months of age.  The DKO IIIA and DKO IIIB mice showed 
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impaired performance and were statistically different from all parental lines. In 
particular, the DKO MPS IIIB mice were significantly different from the parent MPS 
IIIB strains at 3, 5, and 6 months (p≤0.0245). In conclusion we identified an 
accelerated form of MPS IIIB within a DKO model system which showed white 
matter changes, with attendant performance deficits and a drastically shortened 
lifespan. This was in stark contrast to our expectations of a salutary response to the 
elimination of GM2. While contrary to our expectations, the accelerated pathology 
and clinical signs seen in these mice represent an improved system with which to 
study the MPS IIIB mice and their response to therapies. It may also be a useful 
model to investigate white matter pathogenesis as well as the role of complex 
gangliosides in animals with MPS III. Another KO technology which could accelerate 
MPS III disease research involves a conditional knockout strategy applied to MPS 
IIIC. The HSGNAT gene product which is deficient in MPS IIIC is a membrane 
bound protein which is not subject to cross-correction from other cells. By using a 
Cre-loxP recombination system to conditionally knockout HSGNAT gene in MPS IIIC 
mice, studies could focus on the specific aspects of the disease, both temporally, 
and by tissue and cell type. To this end we also constructed a knockout plasmid 
vector, pBY49 under the control of the PGK promoter, which targeted the HSGNAT 
mouse locus. Together these studies have potential to contribute important 
knowledge and resources to MPS targeted research. 
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CHAPTER 1: MUCOPOLYSACCHARIDOSIS TYPE IIIB 
Introduction 
Mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome 
type B (OMIM 252920), is an inborn error of metabolism which is also classified as a 
lysosomal storage disease (LSD) [1]. The disorder is an autosomal recessive 
condition caused by mutations in the NAGLU gene which lead to deficient activity of 
N-acetyl-α-D-glucosaminidase (Naglu, EC 3.2.1.50), and resultant primary lysosomal 
accumulation of the glycosaminoglycan (GAG) known as heparan sulfate (HS) [2]. 
The clinical phenotype of MPS IIIB includes signs such as behavioral abnormalities 
and neurodegeneration, and leads to death in the second decade [1, 2]. Type IIIB is 
one of the four biochemical subtypes of MPS III, which are designated IIIA-IIID [2]. In 
the aggregate MPS III has an incidence of 1 in 73,000 live births [1]. The genetics, 
molecular biology, and enzymology of the NAGLU locus and its enzyme product 
have been studied from both normal and MPS IIIB affected subjects, extending from 
the DNA to the protein level [1]. As a review and introduction, herein we will discuss 
the normal and mutant NAGLU gene and enzyme function including gene structure 
and transcription, message production, maturation, and translation, and enzyme 
modification, trafficking, and function. This introduction will cover the genetics, cell 
and molecular biology of NAGLU gene and its resultant enzyme in the normal and 
diseased state, and briefly will introduce the conceptual approaches to treating MPS 
IIIB based on the variety of known mutations. Work done on the NAGLU gene or 
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enzyme will be included, but where no specific examples of NAGLU or MPS IIIB 
exist in the literature, appropriate work on similar or related LSDs will be included. 
The NAGLU Gene and Enzyme in the Normal State 
Human NAGLU gene description 
The human NAGLU gene was cloned in 1996 [3], and spans 8.5 kbp. The gene 
maps to chromosome 17q21. The gene has six exons interrupted by five introns [3]. 
Typical for housekeeping genes, the 5’ flanking region of the NAGLU gene contains 
a CG rich region, but lacks clearly discernible TATA or CAAT boxes in the expected 
locations [4]. Transcription of the NAGLU gene has not been studied specifically but 
doubtless follows transcriptional mechanisms typical of such genes in the nucleus, 
including three steps; initiation, elongation, and termination. Initiation involves 
formation of a preinitiation complex of up to a dozen subunits of transcription factors, 
including TFIID (including the TATA binding protein or the TBP subunit), TFIIA and 
TFIIB, and their binding to the sequences upstream of the transcription start site 
often denoted by a TATA box sequence. The fully mature transcription complex 
includes RNA polymerase II, and results in melting, or unwinding, of the DNA double 
helix, the antisense strand of which will serve as the template [5]. Elongation 
involves ATP fueled RNA polymerase II incorporation of nucleotides to the nascent 
RNA [5]. Termination of transcription is seen after the incorporation of a 
polyadenylation signal sequences and associated termination sequences, at which 
point RNA polymerase II releases the pre-mRNA and detaches from the DNA [6, 7].  
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The NAGLU cDNA was cloned and characterized by two research groups. 
Weber et al. characterized a cDNA of 2575 bp in length with a 101 bp 5` un-
translated sequence (UTR) and 245 bp 3` UTR including polyadenylation signal and 
poly A tail [3]. Zhao et al. used primer extension to document a 5’ UTR that extended 
at least 321-332 base pairs upstream of the initiating methionine [2, 3]. These 
authors also noted that since there was no TATA box or SP1 site upstream of the 
putative transcription initiation site, that, in fact, the true transcription initiation site 
may be yet further upstream than 321-332 bp from the initiating methionine [2, 3]. 
The NAGLU gene is considered a house keeping gene. As such, expression 
is expected at roughly uniform and ubiquitous levels in different tissues in the body. 
Northern blot analysis of multiple tissues shows NAGLU mRNA at detectible levels 
in all tissues but thymus, with the highest levels seen in liver, ovary, and peripheral 
blood leukocytes [3]. While the NAGLU promoter has not been studied specifically, 
similar genes, such as that for sulfamidase, the enzyme deficient in MSP IIIA, have 
been studied [4]. The sulphamidase gene promoter, similar to observations made 
regarding the NAGLU promoter, has a CG rich region and lacks a TATA or CAAT 
box. Other transcriptional binding sites identified by a bioinformatics approach 
include SYR, MZF1, and Nkx-2.5 binding sites [4]. 
Four animal models of MPS IIIB have been identified, including emu, bovine, 
canine, and murine models. The MPS IIIB dog model is a naturally occurring model 
[8]. The canine NAGLU gene was isolated and sequenced and shows high 
homology at the structural and sequence level, with the canine NAGLU gene having 
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87% identity to the human NAGLU gene and 84% to the mouse NAGLU gene [8]. A 
knockout mouse model of MPS IIIB was developed in 1999 by disruption of exon 6 
[9]. The mouse Naglu gene is located on chromosome 11 and has a length, 
structure, and sequence with a high level of similarity to the human, canine, and emu 
genes [9, 10]. 
NAGLU RNA processing 
The NAGLU pre-mRNA undergoes a number of modifications typical for protein 
coding genes. The first of these is capping, which is a process involving an addition 
to the 5’ end of the transcript before it is exported to the cytoplasm to protect the pre-
mRNA from exonucleases [11, 12]. Capping is a process closely linked with 
transcription that is catalyzed immediately after initiation by three enzymes: RNA 
triphosphatase which cleaves a phosphate group off the triphosphate in the 5’ of 
mRNA chain; guanylyltransferase which binds a GTP derived GMP to the remaining 
diphosphate at the end of mRNA producing 5’-5’ triphosphate linkage; and two 
methyltransferases which transfer the methyl group from S-adenosylmethionine 
(AdoMet) to the 7-nitrogen of capping guanine and to the methylate 2’-hydroxyl of 
the penultimate nucleotide [11, 12]. In addition to stabilizing the transcript, the 
resultant RNA m7G cap is critical for ribosomal recognition and for mature mRNA 
export from the nucleus [11, 12]. 
Polyadenylation of the pre-mRNA at the 3’ end is a nuclear post-
transcriptional process in which a long chain of AMP is added to the 3’ end by poly 
(A) polymerase (PAP) to produce the poly A tail [7, 11, 13-15]. The signal for this 
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addition is found in the 3’ UTR and is known as the polyadenylation signal 
sequence, and consists of the hexanucleotide AAUAAA, which usually lies 10-30 
bases upstream of the cleavage/polyadenylation site in 3’ end of the pre-mRNA 
chain [7, 13, 15]. This signal is important for both RNA transcription termination and 
for the addition of the poly A tail [11, 15]. The addition of the poly A tail aids in export 
of the mature mRNA, and, by extending the half-life of the mRNA in cytoplasm, it 
has a regulatory role in translation [7, 13-15]. 
Before translation of mRNA to protein may proceed, the pre-mRNA must 
undergo an RNA splicing process [11, 12, 15]. RNA splicing occurs in the nucleus, 
and involves a specialized structure known as a spliceosome which consists of a 
complex of U1, U2, U3, U4, U5 and U6 small riboneucleaoproteins (snRNPs) [12, 
15]. The RNA splicing process occurs by nucleophilic attack of the 2’-OH of the first 
nucleotide of the intron forming a lariat intermediate and another attack by the 3’-OH 
from the free exon on the last nucleotide of the intron then the ends of the exons will 
be ligated and release the looped intron producing the mature mRNA [12, 15]. The 
mature mRNA is transferred through pores in the nuclear membrane in a process 
involving facilitation by proteins specific to mRNA molecules, and then into the 
cytoplasm for the translation process [12, 15]. 
Transcripts can undergo processing that involve alternate splicing, thereby 
leading to proteins of different length and function. The NAGLU gene has not been 
rigorously studied in this regard, but reports of RT-PCR-derived transcripts from a 
testis-sourced library yielded alternate transcripts [3]. Alternative splicing of exon 5 
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was detected, producing two fragments having 250 bp difference [3, 16]. The 
meaning of this finding is unclear, and likely of little significance since at the level of 
Northern blot analysis no alternate species of mRNA were evident [3]. The finding of 
alternate transcripts in the testis library may be related to the sensitivity of the 
techniques used, and to potentially different kinetics of splicing in the testis [3]. No 
physiological role of alternate transcripts has been documented in lysosomal storage 
disease associated enzymes. 
NAGLU mRNA Translation 
The NAGLU mRNA translation to protein occurs in the cytoplasm, and involves the 
mRNA being bound by a ribosomal complex in a process that is common to other 
proteins. To review, the ribosome consists of two parts, a large subunit (60S) and a 
small subunit (40S), each of which consists of ribosomal RNA and riboproteins. 
These subunits are located free in the cytoplasm and both bind the mRNA. This 
complex facilitates the binding of the transfer RNA (tRNA), which on one end 
recognizes the codon on the mRNA strand, while on the other end the tRNA carries 
the amino acid specific to its respective codon. The mRNA, the aminoacyl tRNA 
complex, and the ribosomal complex act together to facilitate the mRNA/tRNA base 
pairing and concomitant elongation of the nascent polypeptide chain. The translation 
process is completed in three steps: initiation, elongation, and termination. 
Translation involves three additional elements; initiation factors 1, 2, and 3 (IF1, IF2, 
and IF3), which bind to the 40S unit of the ribosome to form the initiation complex. 
The pre-initiation complex and the tRNA carrying methionine, amino acid bind to the 
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mRNA near the start codon. In the case of the NAGLU mRNA, nucleotides -3 to +4 
(accAUGG), conform to the “Kozak model” of a strong initiator site for translation 
[17], which involves the addition of the first Met residue of the new protein chain. The 
translation process halts when a so-called stop codon is identified for which there is 
no corresponding tRNA. In the case of the NAGLU mRNA, the stop codon used is 
UGA [15]. 
 The process of mRNA translation by the ribosomal elements is the target of 
many therapeutic antibiotics which are specific inhibitors of bacterial translation via 
their ability to selectively inhibit bacterial ribosomal function. This area of study, while 
seemingly divergent from that of MPS IIIB, has become an important focus of 
therapeutic development. As will be discussed in greater detail below, mutations that 
introduce stop codons prematurely usually have serious consequences on 
translation. However, drug developments based on aminoglycosides, antibiotics 
which alter normal bacterial ribosomal function, now offer a compelling approach to 
therapy by aiding in read through of these mutations in eukaryotic cells. Hence, 
depending on the type of mutation, a broader array of the therapeutic strategies for 
MPS IIIB patients may exist in the future. 
NAGLU and Co-Translational Insertion 
As with all secreted or integral membrane proteins, the growing Naglu peptide 
undergoes co-translation insertion. As the Naglu protein chain grows to around 30 
amino acids, the amino terminal signal sequences of 23 hydrophobic amino acids 
emerge from the large unit of the ribosome through the exit channel. The signal 
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sequence is recognized by signal sequence particles (SRP) which then attach to the 
ribosome, decreasing the rate of the translation process, and forming the ribosome 
nascent SPR complex. The ribosome nascent SPR complex is moved toward the 
ER and attaches to the translocation channel (Sec61) in the ER membrane through 
the SRP receptor. The Sec61 channel is opened upon the binding of the signal 
peptide sequence and SPR is released from the ribosome, thereby letting translation 
proceed to completion with the growing protein chain feeding into the ER through the 
Sec61 channel. The signal peptidase complex (SPC) in the ER membrane cleaves 
off the signal peptide which is released inside the ER lumen [18, 19]. In the case of 
Naglu, sequence analysis predicts the 23 amino terminus amino acids are cleaved 
off. The mature Naglu protein has a predicted length and molecular weight, based 
on predicted amino acid sequence, of 720 amino acids, and 80 KDa [2]. 
Naglu Enzyme Folding and Maturation 
The Naglu enzyme is converted within the lumen of the ER from the native linear 
form into the active functional form by appropriate folding into its three dimensional 
structure. This process is facilitated at the biochemical level by chaperones, an 
example of which are the Hsp 70 family of proteins. The chaperones, in an ATP-
dependent process, bind and stabilize the protein, preventing the aggregation of 
unfolded chains. Hence, chaperones facilitate the maturation of the proteins. 
Molecular chaperones can be general in nature, serving to aid general protein 
folding and quality control, or can be lectin chaperones, which bind specific glycan 
moieties. They can exist free in the ER lumen, or as in the case of lectin 
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chaperones, they may be membrane-anchored. The end result of the concerted 
action of these chaperones is a properly folded protein [19]. 
Enzyme Glycosylation 
Enzyme glycosylation occurs inside the ER and is catalyzed by an oligosaccharial 
transferase (OST), itself attached in the ER membrane. This occurs via N-linkage 
glycosylation by adding an acetyl-glycosyl group to the nitrogen of the aspargine 
residue in the consensus sequence Asn(N) X Ser(S)/Thr(T) where X is any amino 
acid except proline. Naglu has six potential glycosylation sites, based on sequence 
analysis, which are located at aspargine residues 261, 272, 435, 503, 526, and 532. 
In addition there are other potential sites with less commonly used sequence 
recognition; Ans513 and Asn134 [2, 20]. Upon completion of appropriate protein 
folding and glycosylation in the rough endoplasmic reticulum (RER), Naglu is 
packaged into cytosolic coat protein II (COPII)-derived vesicles and transported out 
of the ER to the Golgi [19] for further critical modifications. 
Mannose-6-Phosphorylation and Lysosomal Targeting 
In the cis-Golgi, Naglu is modified at the terminal oligosaccharide residues by the 
addition of mannose-6-phosphate (M6P) moieties. This reaction occur in a two-step 
reaction; the first reaction being the addition of an N-acetylglucosamine phosphate 
group (PGlcNAc) to the mannose residue of the Naglu enzyme. This is catalyzed by 
an N-acetylglucosamine (GlcNAc) phosphotransferase, producing a phosphodiester. 
The second reaction removes the GlcNAc group leaving the Naglu enzyme carrying 
a phosphoralyated mannose, which is catalyzed by a phosphodiesterase. The 
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resultant Naglu carrying an M6P tag binds the M6P receptor in the trans-Golgi 
Network (TNG) forming vesicles which detach from the Golgi apparatus and fuse 
with the endosome which then develops to a mature lysosome [21, 22]. The fused 
vesicles release the Naglu enzyme inside the lysosome due to the acidic pH, 
allowing the M6P receptor to recycle to TNG [23-25]. There is an alternate pathway 
for the Naglu enzyme to be taken directly from the TGN via the M6P receptor 
bearing vesicles to the plasma cell membrane and hence into the extracellular space 
[24]. This secretion is the basis of all in vitro enzyme production, and also allows for 
transplanted or gene therapy transduced cells to secrete enzyme to be taken up by 
non-producing cells via cross-correction. 
Enzyme Structure and Function 
The Naglu enzyme was first associated with MPS IIIB by O’brien in 1972 [26]. Since 
then, the enzyme has been purified and characterized by a variety of laboratories 
[27, 28]. A comprehensive list of Naglu evaluations can be found via the Brenda 
Enzyme Information System [27, 29]. Highly purified Naglu has an estimated 
molecular weight of 82 KDa, which is in good agreement with the hypothetical 
calculation. The pH optimum for enzyme activity is 4.5 ± 0.3, which is consistent with 
what is known of lysosomal enzymes [27]. The enzyme is inactivated easily by heat 
(65 °C), and activity is much diminished at higher pH  (pH < 5) [28]. The structure of 
Naglu has been predicted based on crystallization of a truncated bacterial 
homologue of Naglu, both of which are members of the Glycoside Hydrolase 89 
family of enzymes [30, 31]. The bacterial homologue reveals a protein with four 
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distinct domains. There is an N-terminal domain (a family 32 carbohydrate-binding 
module), followed by a small catalytic domain of α/β structure. The bulk of the 
remaining aspects of the enzyme is composed of an (α/β)8 barrel. 
Naglu Substrate 
Naglu functions to degrade HS [32], which is a specific type of GAG. This is 
accomplished by hydrolytic cleavage of the terminal N-acetylated GlcN residues of 
HS within the low pH of the lysosome. The structure of HS consists of repeats of a 
sulfated disaccharide unit comprised of a uronic acid (either L-glucuronic acid (GlcA) 
or L-iduronic acid (IdoA)) and a GlcN or GlcNAct [33, 34]. The GAGs are presented 
to the lysosome for degradation and are first digested by endoglycosidases. 
Complete digestion requires activity of enzymes like Naglu which operate by 
digestion of sugars in a stepwise fashion form the non-reducing terminus. Laboratory 
measurement of Naglu activity can rely on a tritiated natural substrate [35], or a 
more frequently used 4-methylluberliferone (4MU) based fluorescent substrate. 
Catalytic capacity of approximately 50% of normal levels are well tolerated at the 
whole animal level, as carrier individuals, both human and animal, have been 
completely normal, lacking any abnormal signs [35]. 
MPS IIIB: From Gene to Protein 
Molecular defects underlying MPS IIIB 
Beginning with the human NAGLU gene isolation and cloning of 2.5 kb human 
NAGLU cDNA, it became possible to characterize the molecular defects which lead 
to the clinical phenotype and the brain degeneration in Sanfilippo B patients [2]. 
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Following will be a discussion of examples of the mutations seen in the NAGLU 
gene and their effects on the natural history of the Human NAGLU gene and the 
mechanisms that lead to deficient Naglu enzyme activity. More than 100 different 
mutations of the NAGLU gene have been characterized which are associated with 
MPS IIIB patients: 68 missense, 9 nonsense, 21 small deletions, 10 insertion, and 2 
splice site mutations [2, 32, 36-39]. 
Mutations at the Chromosomal Level 
Large chromosomal mutations leading to MPS IIIB have not been documented. 
Large intragenic deletions have been described only once, leading the elimination of 
exons 3 and 4. Such a mutation was associated with a severe phenotype, with the 
affected child succumbing to her disease at the age of 11 [40]. Partial chromosomal 
deletions are more commonly seen in the similar HS storage disorder Hunter 
syndrome (MPS II), due to the X-linked nature of the disease [41]. 
Mutations Affecting Promoter Function 
To date, no mutations which affect promoter function have been characterized in 
MPS IIIB patients [42]. Given that normal physiology tolerates at least 50% of normal 
levels of enzyme activity, a promoter mutation would have to be considerable, 
leading to substantial diminution of activity [42]. Neither have there been any 
mutations in other MPS or LSD mutations that involve this aspect of the gene [42].  
Mutations Affecting Normal Transcript Maturation and Transport 
Many processes of normal NAGLU mRNA transcript maturation and transport are 
generic to mRNA [43]. Sequence-specific effects that may be disrupted by NAGLU 
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gene mutations could be seen in cases where RNA transcript sequences are critical, 
such as splicing and to a lesser extent, polyadenylation [43]. The later has never 
been documented, but splicing defects are well-recognized [43]. Depending on the 
specific aspects of the mutation and the consequences, various downstream effects 
could be seen, including, deletions of large portions of the normal reading frame, 
with or without frame shifts [43]. A study involving Naglu has addressed this directly 
in the case of an mRNA splicing mutation occurring the intron-exon junction region 
(IVS3+1G→A) [43]. This mutation was evaluated in a cell-based system using COS 
cells. The mutation, which is a substitution of G to A in GT at the splice donor site of 
intron 3, resulted in the skipping of exon 2 and/or 3 [43]. This disrupted the reading 
frame and subsequently no detectable NAGLU protein was seen in metabolically 
labeled COS cells, ostensibly due to stop codon-mediated decay (see below for 
further discussion) [43]. 
Mutations Affecting Normal Translation 
Point or indel mutations which lead directly to stop codons or frame shifts and 
subsequent stop codons, can lead to non-sense-mediated decay of the mRNA, 
which is a quality control system that regulates the destruction of mutant mRNA 
transcripts containing premature stop codons [44]. Two relatively common nonsense 
mutations, W147X and R533X, in NAGLU may will lead to stop codon-mediated 
decay [38]. 
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Mutations Affecting Normal Protein Folding, Maturation, and Trafficking 
Many aspects of the process of protein folding, maturation, and trafficking are 
generic to the RER and the TGN, and one would not expect changes in the Naglu 
enzyme to affect these. Processes which do depend on the primary protein 
structure, and hence potentially affected by mutations, involve protein folding and 
glycosylation. No mutations have been documented to affect glycosylation in Naglu. 
Numerous types of mutations including point mutations and small in-frame indels, 
could theoretically have a serious consequence on normal protein maturation within 
the RER. Such point mutations may produce misfolded enzyme which fail to be 
normally matured or transported. Subsequent retention within the lumen of the RER 
subjects the misfolded protein to a quality control system which distinguishes 
between well and incompletely folded proteins.  Molecular chaperons have an 
essential role to induce and promote the folding of the newly synthesized protein and 
also have alternate roles in a “quality control system” for recognizing retained and 
misfolded proteins. These are targeted for degradation [31]. Molecular chaperons 
consist of the Hsp 70 family and similar proteins, which lead to misfolded protein 
ubiquitination by the E3 ubiquitin-protein ligase CHIP, and followed by subsequent 
degradation via the 26S Proteasome, a large proteolytic complex, in which non-
functional proteins are degraded in an ATP dependent process [45]. Metabolic 
labeling studies have found that a number of missense mutations may lead to 
protein misfolding and subsequent degradation via the proteosome [43]. 
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Mutations that Affect Catalytic Capacity 
Missense mutations that allow for normal enzyme maturation and trafficking which 
are associated with MPS IIIB could result in two theoretical consequences to the 
enzyme. Mutations that severely affect the enzyme’s stability could theoretically lead 
to rapid loss of enzyme activity within the environment of the lysosome. Alternately, 
the enzyme might be stable but have mutations that affect the active site or 
otherwise interfere with substrate binding and catabolism. While the exact 
mechanism has not been studied in these cases, labeling studies of missense 
mutations have demonstrated enzyme which traffic to the lysosome but which 
appears inactive [44]. 
Therapeutics strategies for the CNS in MPS IIIB 
Theoretical therapeutic approaches for treatment of MPS IIIB and/or decreasing the 
lysosomal accumulation of GAGs depend on three basic approaches: enzyme based 
therapy, substrate deprivation therapy, and drug therapy [46]. Enzyme therapy aims 
to increases the Naglu catalytic capacity of the lysosome [47]. Substrate deprivation 
therapy aims to decrease the biosynthesis of the substrate HS, and is, in all 
likelihood only useful as an adjunct or secondary therapy [48]. Drug therapy is, at 
this point in time, a highly theoretical process where a drug therapy could target 
mechanistic effects involved in the clinical signs seen as a consequence of the 
lysosomal accumulation, and, as with substrate deprivation therapy, would, if 
developed, likely act only as secondary or adjunct therapy. 
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Generic and Specific Challenges of MPS IIIB Targeted Therapies 
Inherent difficulties and challenges exist for the successful development of 
therapeutic approaches for the MPS IIIB. In principle, there are two significant 
hurdles currently: one of which is specific to MPS IIIB, and one which is generic to 
the neuropathic LSDs. 
Blood Brain Barrier (BBB) 
The main obstacle for therapy faced by all of the neuropathic LSDs is the BBB since 
the brain blood vessels are lined with endothelial cells which are characterized by 
tight attachments to each other, which leaves no gaps for the larger charged 
molecules to penetrate into the brain [49, 50]. This problem can potentially be 
overcome by using one of the following methods: direct injection or indirect delivery 
of the therapeutics to the central nervous system, high dose therapy that overcomes 
the BBB by as yet unknown mechanism, removal of the sugar side chains of the 
enzyme, and tagging of the enzyme for active transport across the BBB [51, 52]. 
Mannose-6-Phosphate tagging 
Enzyme Replacement Therapy (ERT) is a viable method to treat MPS IIIB via 
intrathecal administration of enzyme. However, for unknown reasons, attempts to 
overexpress human recombinant Naglu (rhNaglu) have led to production of enzyme 
that has virtually no M6P [2, 3]. Such an enzyme will have very poor ability to diffuse 
and be taken up by cells.  
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Therapeutic Approaches That Address Enzyme Deficiency 
Therapy that aims to increase enzyme activity via delivery of the normal gene or 
enzyme is appropriate for mutations that lead to loss of activity from all possible 
consequences mentioned above in our treatment of mutational consequences. 
Because of the ability of M6P-labeled enzyme to traffic to the extracellular space and 
be taken up from that space, exogenously sourced enzyme will have therapeutic 
benefit if the above mentioned production difficulties can be resolved. Certain types 
of therapy directed at increasing endogenous enzyme, as will be described below, 
will be useful only for specific types of mutations. 
Gene Therapy  
The aim of using gene therapy is to deliver the normal gene to deficient cells in the 
central nervous system [53]. Broadly speaking, there are two types of delivery 
systems used for gene therapy, viral vectors and non-viral vectors [33]. Following is 
a discussion of various viral vector systems which have been deployed to treat MPS 
IIIB or similar conditions. 
Adeno viral vectors (Ad)  
An adenoviral vector based on canine adenovirus serotype 2 (CAV-2) was used to 
reduce the innate immune response commonly seen when using the human 
adenoviral serotype 5 vectors. MPS IIIA adult mice were treated with the injection of 
CAV-based vectors into the thalamus and produced short-term gene expression. 
When newborn mice were treated with intra-ventricular injection, it led to long term 
gene expression, at least 20-weeks, and reduced neuropathology of these mice [54]. 
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Adeno-associated viral vectors (AAVs)  
MPS IIIB-affected mice have been treated using AAV2 vectors with the human 
NAGLU cDNA via IV injection, IC injection and combination of IV and IC injection 
[52]. Expression of Naglu enzyme in the brain of mice in IC and IV+IC was detected, 
leading to improvement of mice by behavioral performance and life span. Single IV 
injections of a rAAV9-CMV-hNAGLU vector led to normal or above normal levels of 
Naglu in the CNS. The rAAV9-CMV-hNAGLU corrected the neurological defect in 
the PNS and CNS of the adult MPS IIIB mice and extended their life span and 
improved their behavioral performance [52]. Use of an AAV vector delivered to the 
brain by intraparenchymal injections has also been evaluated in the canine MPS IIIB 
model with a positive result [55].  
Retroviral vectors 
Mucopolysaccharidosis I-affected mice were treated with a self-inactivating (SIN) γ-
retroviral vectors carrying α-L-iduronidase (IDUA) [56]. The IV injection of SIN γ-RV 
reduced the clinical manifestation in the MPS I mice and was hypothesized to result 
in only benign insertional mutagenesis due to the absence of the promoter and 
enhancer in the viral LTR [56]. 
Lentiviral vectors (LV) 
Lentiviral vector-mediated gene transfer has been used to correct MPS IIIB-deficient 
fibroblasts [57]. The mouse model of MPS IIIB was treated with a lentiviral-NAGLU 
vector [58], as has been the mouse model of MPS I [59] and the MPS VII mouse 
model [60]. There are potential effects which may limit use of lentiviral vectors as 
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therapeutic approaches in vivo. In short term lentiviral vector treated animals, 
treatment led to a decrease of GAG accumulation, but in longer term treated 
animals, there was an antibody response directed against the transduced gene 
which was detected in the blood. This problem could be seen to be generic to other 
gene delivery techniques. A concern specific to integrating vectors which are derived 
from retroviridae based vector systems is the concern surrounding insertional 
mutagenesis and potential neoplasias associated with such genomic disruptions. 
This has been documented in human gene therapy treated patients, and has led to 
the development of so called self-inactivating (SIN) vectors [61]. Such vectors are 
being used in combination with stem cell therapy and hold significant promise [62, 
63]. 
Cell Therapy 
Hematopoietic cell transplantation therapy (HCT) or its clinical precursor, bone 
marrow transplantation therapy (BMT), have been used successfully in treating 
specific types of MPS. It is the standard of care for Hurler forms of MPS I, but has 
also been evaluated in MPS VI, and MPS VII [33]. But for unknown reasons, HCT as 
currently practiced is unsuccessful in treating MPS IIIB disease [33]. 
Enzyme Replacement Therapy (ERT) 
The supplementation of MPS IIIB patients with recombinant Naglu enzyme, via IV or 
intrathecal injections is a possibility, but at this point practical and regulatory issues 
have not been addressed, since a commercially available product is not available for 
such therapy. Such a therapy is available or under development for MPS I, II, and 
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IIIA [64]. As mentioned, a critical hurdle to be overcome is the issue of insufficient 
M6P in preliminary studies. 
Enzyme Enhancement Therapy (EET) 
This therapy, also known as pharmacological chaperonin therapy, pharmacoperone 
therapy, or small molecule therapy, is based on small molecules used as active-site-
directed compounds that may aid in normal protein folding in the RER, working as a 
functioning template in the RER to protect the enzyme from degradation in the RER 
by the quality control system. This may allow a cDNA with a point mutation that 
affects protein folding but not catalytic activity to result in protein that matures 
normally and reaches the lysosome [33]. Indeed, recent structural analysis of Naglu 
was aimed at developing this specific type of therapeutic [30, 31]. This therapy, if 
successfully developed, will possibly only address the defect in a specific set of 
patients with mutations that may be suitable for this therapy, i.e. patients with point 
mutations only affecting folding. However there may be generic effects of these 
compounds that will increase the half-life of the enzyme in the lysosome, and in that 
regard they may have broad utility as adjuncts to other enzyme based therapies. 
Stop Codon Read-Through Mediated Therapy 
Stop codon read-through meditated therapy involves the use of a small molecule to 
induce read-through of the premature stop-codon mutations [44, 46]. This would 
theoretically be a useful approach in the context of point mutations which lead to 
stop codons as described above in MPS IIIB patients [44]. Antibiotics such as 
gentamycin, which target the ribosome, have been used as treatment for MPS I 
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syndrome [44], and this general approach is under development to identify related 
drugs which have more potent effects on stop codon read-through [44, 46]. 
Therapeutic Approaches That Decrease Substrate Load 
The main goal for the substrate reduction therapy is to balance the synthesis and 
degradation of the substrate and let the lysosome function normal [48]. Genistein is 
a soy derived isoflavone used to inhibit synthesis of HS and consequently the HS 
lysosomal accumulation in MPS IIIB [65]. While this therapy is unlikely to provide a 
primary therapy to MPS IIIB patients, the basic approach is medically sound for 
attenuated forms of some LSDs. An example is the use of N-butyldeoxynojirimycin 
(miglustat, Zavesca) which is an approved therapy for non-neuropathic or type I 
Gaucher disease [33, 66]. 
Drug Therapy 
Drug therapy involves use of an approved pharmaceutical or other small molecule to 
treat the clinical signs and symptoms of disease, as opposed to a treatment that 
addresses the root cause of disease. The recent development of losartan therapy for 
the treatment of Marfan’s syndrome represents a paradigm shift in the way we think 
about treatments of genetic diseases [67]. This shift is one from gene replacement 
or correction to treatments that address the downstream effects of the disease. That 
a multisystem connective tissue disorder such as Marfan’s syndrome could be 
treated by a drug based approach has had a profound impact on the way possible 
treatments are thought of [67-69]. With regards to the MPSs and neuropathic LSDs, 
isolated application of the drug therapy has been successfully used at the animal 
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model stage in two LDSs; the skeletal disorder, MPS VI [70], and the neuropathic 
LSD NPC disease [71, 72]. In the MPS VI rat model, Remicade®, an autoimmune 
drug, resulted in significant joint improvement in this model [70]. In Niemann-Pick 
disease type C1 (NPC), the use of non-steroidal anti-inflammatory drug (NSAID) 
therapy significantly improved life span and slowed the disease course, ostensibly 
by reducing CNS inflammation [71]. The use of cyclodextrin therapy also significantly 
prolonged lifespan, slowed disease progression, and reduced glycosphingolipid 
storage, apparently by reducing neuronal storage of unesterified cholesterol [72]. It 
is a reasonable theoretical possibility that some similar therapy could be found for 
Sanfilippo syndrome. But, since the studies mentioned above found only that 
lifespans were improved but not yet normal, it seems reasonable to expect that any 
future drug therapy will likely play only a secondary or adjunct role in therapy, one in 
combination with a therapy that targets or prevents the primary metabolic and 
cellular effects of the diseases. 
Summary/Conclusion: 
Therapies for the neuropathic LSDs face challenges. The neuropathic diseases face 
specific hurtles involving the BBB. Some therapies show promising improvement in 
treating the neurological defect in LSDs while others fall short. The use of ERT has 
been among the most effective therapy in treating LSDs [73]. High dose of ERT 
using recombinant enzyme produced improvement in the CNS cells in Gaucher, 
Fabry, MPS I, MPS IV, and Pompe disease [74-78]. Hematopoietic cell 
transplantation therapy (HCT) has limitations in treating LSDs, since it has a risk of 
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graft-versus host disease and it has shown efficacy only in Krabbe disease [79, 80] 
and Hurler disease (MPS IH) [81]. Gene therapy using AAV showed efficacy in 
animal models of NPC, MPS IIIA, MPS IIIB, MPS VII, and Krabbe disease [82-87]. 
An SRT based therapy with Miglustat showed effective improvement in Gaucher 
disease [88], the GM1 and GM2 gangliosidoses, and NPC disease [89, 90]. 
Pharmaceutical chaperons have the ability to lead to production of the deficient 
enzyme in the brain using a murine model beta-galactosidase deficiency (GM1 
gangliosidosis) treated with N-octyl-4-epi-β-valienamine (NOEV) [91, 92]. The 
combination of more than one therapy has also been shown to enhance the efficacy 
compared to using only a single therapy [93]. The combination of BMT with SRT (N-
butyldeoxynojirimycin (NB-DNJ)) produced a synergetic effect resulting in increased 
survival of a Sandhoff disease mouse model [94]. In the same model, the 
combination of an anti-inflammatory drug therapy (NSAIDs) with SRT (NB-DNJ), 
produce a synergetic effect in increasing the survival in this model and slowing the 
rate of the disease progression [95]. In the NPC mouse model, the combination of 
NSAIDs with SRT (miglustat) result an additive benefit [71]. In conclusion, it seems 
evident that there is no universally effective therapy either singly or in combination 
for LSDs. Hence the understanding of the pathologic mechanisms remains an 
important point which may aid in finding the most effective therapy, whether such a 
therapy be a single agent or approach, or one which combines various treatments 
for each of the LSDs. Regardless of what approach to therapy is used, initiating 
early treatment, aided by new born screening will be a critical development in 
establishing full treatment effects in patients. [96, 97]. Aided by accurate neonatal 
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screening and a full understanding of the pathogenesis of disease, newly developed 
therapies could be instituted at a stage before irreversible pathology is established, 
thus optimizing patient outcomes.  
Development of LDSs therapy 
The secondary accumulation of gangliosides has been an area of study in the MPSs 
and other related disorders [98, 99]. Additionally, the storage of GM2 is seen as a 
primary storage substrate in a variety of disorders including Sandhoff disease, Tay-
Sachs disease, and the AB variant [100]. While it is known that GM2 ganglioside is a 
secondary accumulation product in the neuropathic MPSs, its clinical significance is 
unknown. We focused on the study of the effect of elimination of GM2 ganglioside 
accumulation on the pathogenesis of MPS IIIB mouse model. If GM2 accumulations 
were eliminated and this showed clinical benefit in the mouse model, it would 
support using a substrate reduction therapy with Miglustat to great MPS IIIB.  
The β-1, 4-Nacetylgalactosaminyltransferase (GalNAcT) mouse 
The enzyme responsible for GM2 ganglioside biosynthesis is β-1, 4-N-
acetylgalactosaminyltransferase (β-1,4-GalNAc-T; EC: 2.4.1.92) and controls the 
synthesis of brain-enriched complex gangliosides by the conversion of GM3, GD3, 
and lactosylceramide to GM2, GD2, and asialo-GM2 (GA2) respectively [101]. The 
GalNAcT deficient mice are unable to produce GM2 ganglioside and are used as 
single knockout (SKO) mice to study the role of complex gangliosides in the CNS. 
Additionally when used in the context of a double knockout (DKO) approach, these 
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mice allow for the study of the role of GM2 ganglioside storage in the pathogenesis 
of LSDs [102].  
Double Knockout Mice Approach 
The DKO mice approach using the GalNAcT null mice has been used in neuropathic 
LSDs to study the effect of GM2 ganglioside elimination on the pathogenesis of 
disease. Sandhoff/GalNAcT DKO mice showed a significant improvement in life 
span and motor function over that of the SKO Sandhoff mice [103]. Unlike 
Sandhoff/GalNAcT DKO mice, NPC/GalNAcT DKO mice didn’t show improvement in 
life span or in the symptoms of the disease [104]. In another study of NPC, 
NPC/GalNAcT DKO mice showed reduction in the unesterified cholesterol, which 
implicated this accumulation as being GM2 ganglioside dependent [103]. 
The Ellinwood laboratory has generated a new model consisting of MPS 
IIIB/GalNAcT DKO mice which have accumulation of HS as the primary storage 
compound, but do not have the ability to produce GM2 ganglioside, and hence, are 
unable to store GM2 as a secondary storage compound, which is a characteristic of 
MPS IIIB. This DKO model showed shorter life span than the SKOs, hind limb 
hyperextension and ataxia. Additionally, we generated an MPS IIIA/GalNAcT DKO 
mice model to confirm that the data from MPS IIIB/GalNAcT DKO mice model 
resulted from a specifically HS storage dependent effect. 
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Chapter 2 
All analysis and writing was done by Eman Mohammed. Eman Mohammed 
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assistance on analysis). Gene therapy injections of DKO mice was conducted by 
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Eman Mohammed and Rafi Awedikian, who also designed Fig. 4. 
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Abstract 
Mucopolysaccharidosis type IIIB (MPS IIIB) is a neuropathic lysosomal storage 
disorder (LSD) resulting from an inherited deficiency of N-acetyl-α-D-
glucosaminidase (Naglu) activity, an enzyme required to degrade the 
glycosaminoglycan heparan sulphate (HS). A deficiency in Naglu activity leads to 
lysosomal accumulation of HS as a primary storage substrate, and the gangliosides 
GM2 and GM3 as secondary accumulation products. To test the effect on 
neuropathogenesis of ganglioside accumulation, we bred mice deficient in both 
Naglu and GalNaAcT activity. The latter is the enzyme required for synthesis of GM2 
and other complex gangliosides. Contrary to our expectation and to double knockout 
(DKO) studies where GalNAcT was knocked out in combination with other LSDs, our 
DKO mice showed a drastically shortened lifespan (24.5 ± 1.4 weeks, versus 50.5 ± 
0.9 wks (MPS IIIB), and 38.6 ± 1.2wks (GalNAcT)). To confirm that HS storage was 
the primary element resulting in the accelerated disease in our DKO mice, and not a 
locus tightly linked to the Naglu gene, we replicated our study with MPS IIIA mice, 
and found a virtually identical result (27.5 ± 1.8 weeks, versus 53.8 ± 1.6 wks.). All 
DKO mice showed motor signs of hind limb ataxia and hyper-extension, which were 
not seen in single KO or normal mice. At approximately 5 months of age the MPS 
IIIB DKO showed a unique pattern of vacuolization and nerve fiber degeneration in 
the corpus callosum as well as the relatively early intracytoplasmic vacuolation of 
many neurons and glia, the latter being a characteristic of the MPS IIIB mice. We 
analyzed motor performance on a rocking Rota-Rod beginning at 3 months of age.  
The DKO IIIA and DKO IIIB mice showed impaired performance and were 
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statistically different from all parental lines. In particular, the DKO MPS IIIB mice 
were significantly different from the parent MPS IIIB strains at 3, 5, and 6 months 
(p≤0.0245). In conclusion we identified an accelerated form of MPS IIIB within a 
DKO model system which showed white matter changes, with attendant 
performance deficits and a drastically shortened lifespan. This was in stark contrast 
to our expectations of a salutary response to the elimination of GM2. Despite this, 
the accelerated pathology and clinical signs represent an improved system to study 
the MPS IIIB response to therapies, and may be important to investigate 
neuropathogenesis as well as the role of complex gangliosides in normal CNS 
function. 
 
Keywords: Double knock out models, Mucopolysaccharidosis type IIIB (MPS IIIB), 
GalNAc Transferase. 
45 
 
 
Introduction: 
The mucolpoysaccharidoses (MPSs) are inborn errors of metabolism that are 
classified as lysosomal storage diseases. An individual MPS condition results from 
deficient activity of a specific lysosomal enzyme, which leads to lysosomal 
accumulation of glycosaminoglycans (GAGs). Mucopolysaccharidosis type IIIB 
(MPS IIIB, OMIM 252920) is an autosomal recessive syndrome characterized by 
deficiency in N-acetyl-α-D-glucosaminidase (Naglu, EC: 3.2.1.50) activity which 
leads to lysosomal accumulation of the GAG heparan sulfate (HS). Clinical signs 
include childhood onset of hyperactivity and progressive mental retardation ending in 
dementia and premature death, usually in the second decade [1]. In addition to 
primary storage of HS, MPS IIIB patients and animal models accumulate the 
gangliosides GM2 and GM3 in the central nervous system (CNS), by as yet 
imperfectly understood mechanisms. The GM2 ganglioside accumulation has an 
unknown role in the clinical phenotype of MPS IIIB but given its presence as a 
primary or secondary storage product in many other lysosomal storage diseases, we 
pursued a DKO mouse experiment to investigate the role of GM2 accumulation on 
the murine MPS IIIB phenotype. Importantly, if GM2 accumulation could be found to 
play a significant clinical role, there exists the theoretical opportunity to limit this 
accumulation via a drug based substrate reduction therapy using miglustat, a drug 
approved as an agent for Gaucher disease [2]. 
 All of the neuropathic MPSs (types I, II, IIIA, IIIB, IIIC, IIID, and VII) store HS 
as a primary substrate. An essential component of the nerve cell membrane as part 
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of membrane bound proteoglycans, HS, when stored as part of the pathology of the 
neuropathic MPSs, causes progressive mental deterioration by incompletely 
elucidated pathological mechanisms. Additional to the primary storage of HS, all of 
these MPS disorders have lysosomal accumulations of GM2 and GM3 gangliosides 
as secondary storage products [1, 3-11]. The accumulation of gangliosides in the 
central nervous system is characteristic of two major groups of diseases; diseases 
with primary ganglioside storage which include GM1 and GM2 gangliosidosis and 
related conditions (Sandhoff, Tay-Sachs, AB variant, etc.), and diseases with 
secondary ganglioside storage, which include Niemann-Pick disease, Gaucher 
disease, the glycoproteinoses, the mucolipidoses, and the neuropathic 
mucopolysaccharidoses [12]. In the primary gangliosidoses storage disorders, 
ganglioside accumulation is associated with progressive neurodegeneration. It is 
unknown what contribution the ganglioside accumulations make when they 
accumulate as part of a secondary process. 
 A DKO mouse approach has been used to evaluate lysosomal storage 
diseases with ganglioside storage in the context of a DKO system involving mice 
with β-1, 4-N-acetylgalactosaminyltransferase (GalNAcT, EC: 2.4.1.94) deficiency. 
This deficiency renders animals unable to produce GM2 and other complex 
gangliosides, and hence they will be unable to store GM2 as part of any pathological 
process. The GalNAcT KO mouse has been used as a single KO to investigate the 
elimination of complex gangliosides on normal function [13-18], as DKO mice to 
invest the role of complex ganglioside in the CNS [19-21] and to investigate the role 
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of complex gangliosides in LSDs [19, 22-25]. The elimination of GalNAcT activity 
results in a complete block in the production of complex gangliosides which include 
GM2, and results in the formation of only GM3 and GD3 and O-Acetylated GM3 [16, 
26]. When used as part of a so called genetic substrate elimination therapy, as was 
done with the GalNAcT X Sandhoff disease DKO, the results were characterized by 
a very marked improvement in the neurologic function and lifespan than that of the 
single KO Sandhoff mice [27]. In contrast to the Sandhoff disease DKO mice, 
Niemann pick type C (NPC) disease DKO mice didn’t show significant clinical 
improvement in the NPC phenotype [28], despite the alleviation of NPC cholesterol 
storage, which was shown in this model system to be ganglioside dependent [18, 
29]. 
 Herein, we report our findings on the MPS IIIB/GalNAcT DKO model, and 
present additional data on extension of this approach to the MPS IIIA mouse model, 
and offer preliminary data on the utility of the MPS IIIB/GalNAcT model to be used in 
evaluations of MPS IIIB directed therapies. 
2.0 Materials and methods 
2.1 Mice 
Institutional Animal Care and Use Committee and Institutional Biosafety Committee 
protocols were approved for all murine studies through the Office for Responsible 
Research at Iowa State University. The MPS IIIB mice (B6.129S6-Naglutm1Efn/J) 
were supplied by Jackson Laboratory and GalNAcT mice (B6.129S-Galgt1tm1Rlp) 
were supplied by the Consortium for Functional Glycomics, through Dr. Paulson at 
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The Scripps Research Institute, LA Jolla, California. Breeding and experimental 
animals were housed in Iowa State University Laboratory Animal Resources 
facilities. Animal rooms were held at 68-79 °F, with ~ 40% humidity, were equipped 
with light timers on a 12 hour cycle, and had 10-15 air changes/hr. At or before 
reaching IACUC approved humane endpoints, mice were euthanized by CO2 
asphyxiation, or, in the case of tissue collection, by exsanguination/perfusion 
following surgical anesthesia with IP administered triboromoethanol (20µl/g body 
wt.), both methods approved by the American Veterinary Medical Association 
guidelines on euthanasia [30]. 
 Genotyping of mice used DNA from 2mm mouse pup tail clippings extracted 
by the HotSHOT protocol [31]. The resultant samples were used in PCR 
amplification reactions to genotype mice at the GalNacT and Naglu loci. The primers 
and sequences used to amplify the Naglu wild type and mutant allele were derived 
from those used by The Jackson Laboratory. For the normal Naglu allele they were 
oIMR5056 5`-GTCGTCTCCTGGTTCTGGAC-3` (forward) and oIMR5057 5`-
ACCACTTCATTCTGGCCAAT-3` reverse. For the mutant Naglu allele we used the 
Naglu forward primer with a mutation specific neomycin primer, oIMR8162 5`-
TGGATGTGGAATGTGTGCGAG-3`. To amplify the wild type GalNAcT allele we 
used T7SF ACACGTGGAGCACTACTTCATG (forward) with 8AR 
AGGTCCAGGGGCGTCTTCT (reverse). For the GalNAcT mutant allele we used 
T7SF with Neo2-ASR CCTGCGTGCAATCCATCTTGTTC (reverse). The conditions 
for the Naglu reactions were 94 °C 3 min followed by 40 cycles of 20 s at 98 °C, 1 
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min at 67 °C, and 1 min at 72 °C with a final exten sion step of 10 min at 72 °C. The 
conditions for the GalNAcT reactions were 10 min at 94 °C, 10 s at 98 °C followed 
by 45 cycles of 98 °C 20 s, 58 °C 30 s, and 72 °C 30 s wi th a final extension step of 
10 min at 72 °C. All reactions were carried out using a  Bio-Rad-My Cycler thermal 
cycler, and consisted of a final volume of 20 µl containing 0.5 unit of Taq polymerase 
and 4 µl of extracted DNA. Resultant PCR products were run on 2-3% agarose gel 
and visualized with SYBR® Safe DNA gel stain. Amplification yielded amplicons 
predicted to be 596 bp (normal GalNAcT) or ~300 bp (mutant GalNAcT) for 
GalNAcT, and 250 bp (normal Naglu) or 270 bp (mutant Naglu). 
2.2 Behavioral and clinical monitoring 
The colony was monitored by visual inspection for pregnancy, births, weaning, 
injury, and illness. They were checked twice a week by observation of their behavior, 
movements, body conditions, and size. Humane endpoints for this study involved but 
were not limited to the following: a severe hunched posture, very low body condition, 
inability to walk, weakness in the hind limbs, hyperextension of the hind limbs and 
associated difficulty in movement, severe and grossly observable urine retention, 
severe and ongoing vaginal or rectal prolapsed. Mice thus observed were 
euthanized as described above. 
2.3 Life span 
Survival analysis was done by using the Kaplan-Meier survival method [32] for the 
live spans of six groups; normal controls, MPS IIIB, GalNAcT, MPS IIIB DKO, MPS 
IIIA, and MPS IIIA DKO mice. Animals were included if they had survived past 6 
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weeks of age (weaning plus 3 weeks). Censored animals included animals 
euthanized for non-disease associated reasons seen in the background strains such 
as malocclusion, non-disease associated skin lesions, head tilt, and, in the case of 
breeding females, dystocia. 
2.4 Rota-Rod 
Rota-Rod testing was performed as described previously [33]. This method indirectly 
measures a combination of factors including coordination, balance and strength and 
employed an Ugo Basile Microprocessor Controlled Rota-Rod Treadmill (Stoelting 
Co., Wood Dale, Illinois). The machine parameters were a fixed speed of 10 
revolutions per minute with the direction of revolution changing once every complete 
revolution. The mice were started training at two months of age and every 4 weeks 
thereafter until death or euthanasia. Time to first fall was recorded. If an animal did 
not fall, they were scored at 300 seconds, the maximum time on the Rota-Rod. Data 
assessed statistically was time to fall by month of age. 
2.5 Ganglioside 
Gangliosides were isolated and analyzed as described [27, 28, 34, 35]. Following 
total brain homogenization and extraction of polar lipids, brain gangliosides were 
separated using HPTLC (TLC-silica gel 60 F, Merck, Darmstadt, Germany) 
according to the published protocols. Plates were then stained and charred to 
visualize bands. 
2.6 Histology 
Tissues fixed in 4% paraformaldehyde were derived from drop fixed samples or from 
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perfused mice, and were paraffin embedded, sectioned (5uM), and stained with 
hematoxylin and eosin (H&E). Assessment of tissues was done by an American 
Board of Veterinary Pathology Diplomated pathologist (EMW). 
2.7 Gene Therapy 
In a preliminary experiment, one DKO MPS IIIB mouse was treated at birth with an 
adeno-associated viral vector containing the human Naglu cDNA (AAV-hNaglu) 
under the control of the hybrid cytomegalovirus enhancer/chicken beta-actin (CAG) 
promoter and containing the bovine growth hormone polyadenylation signal. The 
AAV-Naglu vector used was an AAV2-8 pseudotyped vector and was supplied by 
the University of Iowa vector core. Vector administration involved intravenous 
injection via the superficial temporal vein at ~3 days of age with 50 µl containing 5 x 
10E10 AAV-Naglu particles. Blood serum was assayed from samples withdrawn 
approximately weekly via the saphenous vein. The Naglu assay of serum used a 
4MU based substrate following published protocols [36]. 
2.8 Statistical analysis 
We employed SAS statistical software and held our statistical level of significance 
at α = 0.05. The survival analysis was done using the Proc Life test of SAS followed 
by a log Rank as the post hoc test. The behavioral comparison between the different 
groups was analyzed by one way ANOVA, followed by Tukey-Kramer post hoc, and 
a mixed linear model followed by Tukey-Kramer post hoc. 
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3.0 Results: 
3.1 Mouse production, and clinical progression 
We evaluated over 1023 mice including 643 unaffected controls, 270 MPS IIIB, 64 
GalNAcT, 17 MPS IIIB DKO, 21 MPS IIIA, and 8 MPS IIIA DKO mice. Based on 
PCR derived genotypes, the breeding of mice yielded expected frequency of live 
animals based on Mendelian inheritance. After weaning, the mice were evaluated 
twice weekly with the following results. The average and approximate clinical signs 
observed in our six groups were as follows. The MPS IIIB and MPS IIIA mice 
showed enlarged bladder, often with vaginal or rectal prolapsed at nine months to a 
year of age, at which time they were euthanized according to the humane endpoints 
described in Material and Methods. The MPS IIIA and IIIB mice were grossly 
indistinguishable, and the clinical signs of both included onset at approximately 6 
months of age of an absence of a normal adult level of abdominal fat. At 
approximately 9-12 months of age, bladder enlargements were evident as a 
palpable abdominal mass which was also grossly observable. Males manifest a 
rougher than usual pelage at this time. On average these signs continued for 
approximately one month until animals required euthanasia on humane grounds. As 
stated these criteria are related to bladder enlargement and included vaginal, 
penile/preputial, and rectal prolapses, and/or extreme enlargement of the bladder. 
On gross necropsy, findings of note included a lack of abdominal fat, extremely large 
bladders (volumes collected at necropsy approached 5 ml), with occasional 
hydronephrosis. All the DKO mice manifested grossly observable clinical signs by 
four to 8 weeks of ages which consisted of a hyperextension of the hind limbs at the 
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level of the stifle joint, which was prominent at rest, but not grossly evident during 
ambulation. This manifestation appears stable until approximately 20 weeks, at 
which time animals appear with severe hind limb weakness and ataxia affecting 
ambulation, and hence access to food, and a resultant decline in body condition. At 
this time other signs noted might include rough hair coat which was easily shed, and 
urine scalding especially in males. From onset these signs progress rapidly over 
approximately 4 weeks until animals were euthanized for humane considerations. At 
necropsy grossly observable signs include an enlarged bladder, low body 
conditioning and lack of body fat. The GalNAcT showed no grossly observable 
clinical abnormalities at any age. 
3.2 Survivorship and lifespan 
A Kaplan-Meier survival analysis was done for all mice groups (Fig. 1) as described 
above (Kaplan & Meier, 1958). The MPS IIIB DKO mice had significantly (P < 
0.0001) shortened survival compared to the single knockout MPS IIIB and GalNAcT 
mice ((24.5 ± 1.4 weeks, versus 50.5 ± 0.9 wks (MPS IIIB), 38.6 ± 1.2 wks 
(GalNAcT)). Double KO MPS IIIA mice also had significantly (P <0.0001) shortened 
survival compared to the single KO MPS IIIA and GalNAcT mice ((27.5 ± 1.8 weeks, 
versus 53.8 ± 1.6 wks (MPS IIIA), and 38.6 ± 1.2 wks (GalNAcT)). In summary, all 
DKO mice had statistically different survival compared to parental strains (P < 
0.0001). However the DKO MPS IIIA and MPS IIIB mice were not statistically 
different in survival (P = 0.20). 
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3.2 Rota-Rod 
Rota-Rod testing was performed as described above and yielded significant results 
indicating impaired ability in the DKO groups. We analyzed the Rota-Rod data using 
repeated measures ANOVA, assessing six groups of the mice; Normal (unaffected), 
MPS IIIA, MPS IIIB, GalNAcT, DKO MPS IIIB, and DKO MPS IIIA. The DKO IIIB 
mice were significantly different from the parent MPS IIIB strains at 3, 5, and 6 
months (p≤0.0245), from the normal mice at 3-6 months (p≤0.0377), and from the 
GalNAcT mice at 6 months (p=0.0002). The DKO IIIA mice were significantly 
different from the parent MPS IIIA strains at 3-6 months (p≤0.0004), from the normal 
mice at 3-6 months (p≤0.0 38), and from the GalNAcT mice at 4,5 and 6 months 
(p=0.0047). The DKO IIIB and DKO IIIA mice were statistically different at 4 months 
(P = 0.0146) (Fig.2). 
3.2 Glycosphingolipid Biochemistry 
To confirm the ganglioside profiles in the brains of our various groups, we assessed 
whole brain ganglioside content by HPTLC chromatography as described. Among 
the GalNAcT-/- mice, there was a total absence of GM2, with the predominant 
species of gangliosides being GM3 and GD3. As observed previously [15, 27, 28], 
there was a prominent band consistent with O-acetylated GD3 in all strains of mice 
which lacked GalNAcT activity. The MPS IIIB affected mice had, as expected, visible 
bands indicating an increase in GM2, GM3, and GD3 (Fig. 3). 
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3.3 Histology 
The histological sections of a 22 week old normal mouse (Fig 4A-4C) showed 
histologically normal microglia. The neurons (≥ 95%), likewise appeared normal. 
Purkinje cells were judged to be 90-95% continues, with 100% continuity noted in 
the dorsal and medial folia, and 90-95% ventral and lateral folia. Within the choroid, 
scattered cells had small to large vacuoles (10-20%). 
 In the histological sections of the 22-week-old MPS IIIB affected mouse (Fig 
4D-4F), approximately two third of the microglia distributed uniformly throughout the 
CNS showed moderate levels of clear vacuolation characterized by multiple large 
clear vacuoles. This vacuolation was seen in microglia associated with both the 
perivascular space as well as neurons. Approximately 50% of the neurons 
throughout the CNS had vacuoles, with generally smaller intracytoplasmic vacuoles 
than those seen in the microglia. In some large neurons, especially Purkinje cells, 
the vacuolation approached, in size and number the vacuolation seen in microglia, 
but the general impression was of vacuoles with a finer granularity relative to the 
microglia. The neuronal vacuolation was noted in the cortical neurons, Purkinje 
neurons, hippocampal neurons, and in brain stem nuclei. Purkinje cell numbers 
appeared adequate and normal. Nuclei populations were variable with some 
populations showing moderate and some mild levels of vacuolation. White matter 
throughout, including the corpus callosum, appeared normal, with the exception that 
approximately 10% of the perivascular microglia showed vacuolation of a sort seen 
in the gray matter. Choroidal epithelium showed uniform vacuolation over 90% of the 
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cells with a mix of sometimes single large vacuoles amidst a background of fine 
vacuolation. Ependymal cells showed regional and intermittent mild fine 
intracytoplasmic vacuolation. Leptomeniges in virtually all areas of the CNS showed 
vacuolation in a combination of fibroblast-like and microglial-like cells, which varied 
from mild to moderate. Endothelial cells showed no notable pathology. 
 Histological lesions were not observed in the brain of 22-week-old GalNAcT 
(Fig 4G-4I) affected mouse. It showed no vacuolation in white matter, and <10% of 
the choroid cells had a small number of large vacuoles. Neurons showed no 
vacuolation, and neither were microglia vacuolated. The leptomeninges, neuropil, 
and ependyma showed no vacuolation or abnormalities. 
 In the brain of the 21-week-old DKO MPS IIIB mouse (Fig 4J-4L), 
approximately ~4/5 of the microglia showed moderate to marked levels of clear 
vacuolation characterized by multiple large clear vacuoles, uniformly through the 
CNS, and was seen in microglia associated with both the perivascular space as well 
as neurons. The general impression is one of greater severity than was seen the 
similarly aged single knockout. Approximately 80% of the neurons throughout the 
CNS had vacuoles, with generally smaller intracytoplasmic vacuoles than seen in 
the microglia. In Purkinje cells the same degree of vacuolation was also noted with 
some degree of drop out, with potentially. This loss ranged from 15% in some folia to 
near normal in others. The overall impression was that the ventral and lateral folia 
were more severely affected. Hippocampal and brain stem nuclei neurons showed 
equivalent vacuolation to other neuronal populations. White matter throughout, 
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including the corpus callosum, showed uniform and marked pallor and vacuolation in 
both cell bodies and axons, with an impression of tracts with 50% the normal color 
density expected.  Histological finding throughout were severe but may have been 
slightly worse in the corona radiate than in the corpus callosum. Choroidal 
epithelium showed uniform vacuolation, with over 90% of the cells showing a fine 
vacuolation with sometimes a mix which included single large vacuoles. Ependymal 
cells showed regional moderate fine intracytoplasmic vacuolation. Leptomeniges 
showed vacuolation in a combination of fibroblast-like cells and microglia, in virtually 
all areas of the CNS, which varied from moderate to marked. Endothelial cells 
showed no notable pathology. Neuropil in this animal showed widespread pallor and 
vacuolation throughout. This was not associated with adjacent neuronal soma, and 
greater severity was seen in the periventricular regions. 
 The brain of the 33-week-old, DKO MPS IIIA mouse showed lesions 
remarkably similar to the MPS IIIB/GalNAcT knockout (data not shown), with marked 
intracytoplasmic vacuolization in microglia and neurons, and severe vacuolization of 
the white matter of corpus callosum. There was server regional loss of Purkinje, 
which ranged from 90-95% loss in the ventral lateral folia, to 10% loss dorsal and 
medial folia. Vacuolation in white matter was indistinguishable from that of MPS 
IIIB/GalNAcT DKO. 
3.4 Gene Therapy 
An MPS IIIB DK mouse was injected at two days of age. The animal survived to an 
age of 50 weeks, at which point it was euthanized for complications associated with 
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urine retention. The assays of Naglu enzyme activity demonstrated persistent and 
elevated serum activity between carrier and normal levels. 
Discussion: 
 The current study was motivated by the potential to identify a treatment option 
for MPS IIIB. In stark contrast to our expectations, the genetic elimination of GM2 
and other complex gangliosides had a strong synergistic and deleterious effect on 
the clinical course of murine MPS IIIB. Despite the lack of positive findings in terms 
of treatment effect, the elimination of complex gangliosides using the DKO approach 
may prove a valuable tool in both studying the pathology of neuropathic MPS 
disorders as well as offering an improved model to assess therapy with earlier time 
points for evaluation, thus improving the speed of proof of principle studies in mice. 
 In the present study, the elimination of complex gangliosides in the DKO mice 
showed significant decreases in neurological function and lifespan. By extending the 
MPS IIIB study to the MPS IIIA mice we confirmed that this deleterious effect is the 
direct effect of heparan sulfate storage which exacerbates, in conjunction with a 
GalNAcT null phenotype, the clinical course of disease. This is in stark contrast to 
the findings of the DKO studies involving Sandhoff and NPC disease mice. The 
exact mechanism of this accelerated MPS III phenotype is at this time unclear. 
Potential explanations and subjects for future investigation involve further 
characterization of the white matter diseases involved. However in some respects 
the MPS IIIB DKO phenotype can clearly be seen as an accelerated form of MPS 
IIIB. The DKO mice showed serious bladder emptying abnormalities far earlier than 
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those seen in the single knockout mice. This clinical finding is seen in the context of 
early, novel, and overt neurological disease in the DKO mice. Together these 
findings argue for a neurogenic origin involving disrupted micturition. Up to this time 
it has been unclear whether the urine retention seen in MPS III mice was neurogenic 
in origin or was primarily an outflow obstruction issue. Some literature, based on 
histological findings, has focused on the later [37]. Data presented herein would 
argue for a strong neurogenic contribution to the phenotype. 
 The DKO MPS IIIB mice brain sections showed neuronal vacuolization 
normal for MPS IIIB mice at this age, and a prominent axonopathy, with nerve fiber 
degeneration in the corpus callosum (Fig. 4). The later was entirely absent from age 
matched MPS IIIB controls. Nor was this degree of prominent axonopathy seen in 
the single GalNAcT KO mice. It was noted to a much lesser degree in an aged and 
treated MPS IIIB KO mouse. The exact nature of the white matter lesions bears 
further investigation. It is unclear whether this is primarily a problem of myelination, 
demyelination, or axonal dropout due to neuronal loss. There was no grossly 
observable neuronal loss which would support the latter. Examination of mice at 
younger ages, and use of ultrastructural investigations will prove useful in this 
regard. 
The GalNAcT KO mice model has been shown to have white matter 
degeneration at the histological level with only mild clinical signs and a normal 
lifespan [38]. Myelin-Associated Glycoprotein (MAG) and complex gangliosides play 
an important role in axon stability in both CNS and PNS and the binding by MAG of 
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complex gangliosides provides long term axon-myelin stability. Elimination of 
complex gangliosides apparently induces mild white matter degeneration. Like MPS 
IIIB DKO mice, GalNAcT X MAG DKO mice had a progressive neuropathy involving 
loss of axon-myelin stability, axon degeneration, and hind limb ataxia. The DKO 
mice lacked the shorter life span and enlarged urinary bladder of the MPS IIIB and 
IIIA DKO mice, which indicates there is a specific and accelerating effect on the 
white matter degeneration of the accumulation of HS by a process which remains 
unknown.  
 In an extremely preliminary study we have shown that the DKO model of MPS 
IIIB can respond to enzyme based (in this case through a gene therapy delivering 
the native human cDNA), therapy. This preliminary result indicates that the 
especially aggressive form of disease in this DKO model may respond to therapy 
and hence be particularly useful in identifying windows of therapy in the murine 
model of MPS IIIB. Another valuable use of this approach would be to extend it to 
the MPS I, II, and VII murine models, all of which store heparan sulfate, and none of 
which, relative to the orthopedic disease they manifest, have as serious a 
neurological phenotype as do the MPS IIIB and IIIA single KO mice. In the case of 
MPS I and II, these diseases are both more common in children, and there exists 
ERT which could potentially treat CNS disease if regulatory issues and problems of 
the blood brain barrier could be overcome. An animal model system that allows a 
clearer cut evaluation of the CNS response to therapy would be a valuable resource 
in this regard.  
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Figure 1. 
Survival curves by Kaplan
groups from left to right; DKO MPS IIIB/GalNAcT, DKO MPS IIIA/GalNAcT, 
GalNAcT, MPS IIIB, MPS IIIA, and Unaffected mice.
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-Meier (KM) analysis. The life span of the six phenotype 
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Figure 2. 
Rocking Rota-Rod performance and the age of the six phenotype groups, showing 
that the DKO MPS IIIA and MPS IIIB have deficits in performance at 4, 5, and 6 
months of age versus either SKO. 
  
Rocking Rotorod
0
50
100
150
200
250
300
2 3 4 5 6
Months
Se
c
o
n
ds
Gal
MPS IIIA
MPS IIIA/Gal
MPS IIIB
MPS IIIB/Gal
Unaffected
 
70 
 
 
 
Figure 3. 
Thin Layer Chromatograph (TLC) plate for brain lipid analysis showing ganglioside 
accumulation for brains from: 16 wks normal (lane 2), 18 wks MPS IIIB (lane 3), 25 
wks GalNAcT deficiency mice (lane 4), and 23 wks DKO IIIB mice (lane 5). 
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Figure 4. 
Hematoxylin and eosin (H&E) staining of the brain sections from: a 22 week old 
normal mouse (A, B, C); a 22 week old MPS IIIB single knockout mouse (D, E, F); a 
22 week old GalNAcT single knockout mouse (G, H, I); and a 22 week old MPS IIIB 
DKO mouse (J, K, L); Panels A, D, G, and J show cerebral cortex neurons. Panels 
B, E, H, and K show cerebellar Purkinje neurons. Panels C, F, I, and L show corpus 
callosum white matter. All sections of cerebral neurons and Purkinje cells are at 100 
x magnification. Corpus callosum white matter images are at 20 x magnification. The 
MPS IIIB single knockout mouse shows vacuolization in microglia and neuron cells 
of the cerebral cortex (4D), vacuolization of Purkinje cells of the cerebellum (4E). 
The 21 week-old MPS IIIB DKO mouse shows vacuolization not only in microglia 
and neuron cells but also in the axons and dendrites of the cerebral cortex which 
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appear loosely and much paler (J), vacuolization of Purkinje cell body and in the 
axon and dendrites of the cerebellum (K), and vacuolization of the white matter of 
the corpus callosum (L).  
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CHAPTER 3: RECOMBINANT DNA FOR MPS III RESEARCH  
Introduction 
Our aim in the work presented here was the production of recombinant DNA 
reagents to aid in the study of the pathogenesis of and to improve therapy for MPS 
III. Herein, we focus on two research areas; we generated 1) a conditional knockout 
vector to generate mice to study MPS III pathogeneses in vivo and 2) a vector to be 
used ex-vivo to transduce Hematopoietic Stem Cells (HSCT) to improve therapeutic 
approaches for MPS III. 
Pathology in MPS III; The cellular level in CNS 
MPS III is characterized by clinical symptoms which start at 2-6 years of age which 
include; diarrhea, sleep disturbances, hyperactivity, delayed speech, learning 
disability, and stiff joints without stunted growth. Overall the disease is characterized 
by mental deterioration and CNS degeneration which are somehow triggered by 
storage of the primary substrate HS. While lysosomal accumulation of HS is the 
inciting cause, we do not know the molecular and cellular mechanism of the effect of 
this storage on the clinical deterioration and its specific effect on the brain pathology. 
In previous studies on MPS IIIB mice, vacuolization in both microglia and neurons 
has been detected in the brain. Also, cytoplasmic inclusion of hyperphosphorylated 
tau (P-tau) have been found in dentate gyrus neurons so that it appears that MPS 
IIIB is a  tauopathy syndrome, which a key degenerative feature in Alzheimer 
disease [1]. Other previous studies showed microglia activation and inflammatory 
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changes in the brain of MPS IIIB mice [2]. Attenuated plasticity has been shown in 
neurons and astrocytes in MPS IIIB mice [3]. However the specific mechanisms that 
connect the cellular findings and the clinical signs remain unclear and is an 
important area of future research. 
Understanding MPS III; from brain pathology to clinical signs  
The mechanism of how the brain pathology leads to the clinical symptoms of MPS III 
syndrome could be better understood by dissecting the stages of the disease 
pathogenesis or the function of different cell populations within the 
neurodegenerative process so we can know what the root causes of the disease 
pathogenesis are For example, which is a more important contributor to the clinical 
signs: microglial inflammation, neurons or oligodendrocytes dysfunction, etc. By 
using a conditional KO strategy this may be possible to elucidate. 
Conditional knockout technique  
Conditional gene KO mice involve the use of tissue-specific or temporally-specific 
knockout strategies to inactivate or disrupt a specific target gene. The results of this 
gene disruption will be restricted to a single organ or point in time rather than seen in 
the whole body or from birth. This allows for greater isolation of pathological effects 
in an animal model [4, 5]. 
Conditional gene KO approach in the brain 
Conditional KO (cKO) approaches have been successfully done in the developing 
brain to study different cell type functions and also in neurodegenerative diseases to 
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understand disease pathogenesis related to specific cell populations. Examples of 
successful cKO used to answer questions in the developing brain involved the role 
of progeny of radial glial cells in the developing CNS using Cre/loxP system [6]. 
Radial glial cells are precursors for the developing CNS and differ from the 
morphologically similar neuroepithelial cells. A mouse line expressing Cre-
recombinase was used with Cre-recombinase under the control of the hGFAP 
promoter which is expressed in radial glial cell during development of that cell type 
[6, 7]. Using a fluorescent protein expressing mouse cross, radial glial cell progeny 
were isolated from different regions of the CNS including the cortex, ganglionic 
eminence (GE), and spinal cord. Region-specific radial glia cell findings 
demonstrated regional-specific neurogenesis from glial cell precursors [6]. An 
example of a cKO used to elucidate a neurodegenerative diseases can be found in a 
study of Tubular sclerosis complex (TSC). Tubular sclerosis complex is 
characterized by a defect in the TSC1 gene. Affected children have mental 
retardation, autism, cognitive abnormalities, and epilepsy [8]. Using a Cre-IRES-
LacZ mouse line with expression driven under the control of hGFAP promoter, 
researchers investigated the role of astrocyte disturbances in TSC [8] by astrocyte-
specific deletion of Tsc1 expression in mice. The resultant mice showed abnormal 
neuronal organization, seizures, and early death, findings which support an 
astrocyte-specific role in TSC pathology in mice [8].  
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New KO technology for MPS III  
Existing murine models of MPS III include a conventional KO model (MPS IIIB), and 
a spontaneous model (MPS IIIA) both of which have been used to study the disease 
pathogenesis [9, 10]. However conventional KO models of MPS III are limited for 
studying the brain dysfunction in a rigorous temporal, spatial, or cell type specific 
manner. Use of a cKO approach would make this possible. A hurdle to developing 
this approach is the soluble nature for the MPS IIIA and IIIB gene products. Cross 
correction between the different cell populations in a cKO would make such an 
approach unworkable. But in MPS IIIC we can conditionally KO the gene product 
since it is an integral membrane protein, is non-soluble, and hence KOed cells will 
remain KOed. In conclusion, use of MPS IIIC would allow for the development of a 
conditional KO mouse model with which study MPS III pathogenesis at a cellular and 
animal systems level. 
A conditional gene KO model for MPS IIIC disease  
MPS IIIC is one of four types of MPS III, and caused by deficiency of a non-soluble 
lysosomal membrane enzyme, Heparan acetyl CoA: α-glucosaminide 
acetyltransferase (HSGNAT, N-acetyltransferase; E.C. 2.3.1.3). A conditional gene 
KO of MPS IIIC by targeting the HSGNAT gene will allow study of the critical cell 
populations involved in pathogensis of the disease which may aid in development of 
potential treatments for MPS III and the other neuropathic MPSs ; MPS I, MPS II, 
MPS III, and MPS VII.  
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Combination of therapeutic strategies for MPS III  
Hematopoietic stem cells transplantation (HSCT) research has worked successfully 
in MPS I patients if they are transplanted on or before two years of age. Patients 
showed improvement in the clinical phenotype and saw a substantially prolonged the 
life span. The therapeutic window in MPS I to rescue intellectual function appears to 
be before two and half years of age. Later transplants for the Hurler form of MPS I 
see little to no correction of the CNS disease [11, 12]. For unknown reasons HBCT 
has been unsuccessful in preventing the neurological deterioration in MPS IIIB 
patients when transplanted at the much younger age of 8 months [13]. In MPS IIIB, 
the therapeutic window is either closed at an earlier age than seen in MPS I, or that 
the microglial cells differentiated from the hematopoietic stem cell transplant do not 
produce sufficient enzyme needed to treat the MPS IIIB affected CNS. 
Gene therapy augmented HBCT in mouse models 
Examples of LSDs in which a combination of HBCT and gene therapy (GT) have 
been evaluated in mouse models include metachromatic lekuodystrophy (MLD). This 
LSD is caused by a deficiency of the lysosomal enzyme arylsulfatase A (ARSA; EC 
3.1.6.8) and is characterized by myelin degeneration in both CNS and PNS, with 
accumulation of galactosyl-3-sulfate ceramide (sulfatide) in glial cells and neurons. 
Transplantation of HSC which had been genetically modified with a lentiviral (LV) 
vector containing the ARSA gene, was used to treat As2-/- mice model and it led to 
reconstituted activity of arylsulfatase A activity and prevented learning and 
coordination defects and neuronal pathology of the MLD mice [14]. This approach, 
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involving the combination of HBCT and GT has shown positive outcome in the 
improvement in MPS I using the mouse model [15]. The long term purpose of this 
study was the improvement of MPS IIIB treatment by using a combination of GT 
modification of HBCT using a lentiviral vector, followed by autologous transplantation 
into diseased mice, with the goal of producing sufficient activity in the CNS of the 
deficient Naglu. 
Advantages of the combination of two therapeutic strategies for MPS III   
Different treatment strategies which have been developed using the MPS IIIB mouse 
model, as have been described in chapter 1. These strategies, by and large, have 
been used for treatment evaluations in short term murine studies. Our plan was to 
use a long term treatment strategy using the combination of HSCT and GT in the 
MPS IIIB mouse model. Such a therapy has the potential to lead to a widespread 
(including the CNS), stable, and continuous distribution of the recombinant enzyme. 
We consider a combination therapy is required since HSCT alone is a therapeutic 
strategy that has been used in MPS IIIB patients at early age but with very poor 
outcomes [16]. A combination of HSCT and GT has advantages over either HSCT or 
GT may separately. Chief among these advantages include even distribution in the 
brain based on microglia repopulation. Lentiviral vectors are preferred in this role 
due to advantages involving safety which are related to the self in-activated vectors 
which have been develop that inactivate the transcriptional activity of the of the long 
terminal repeat (LTR). 
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Plasmid construction  
A lentiviral vector was used into which was cloned the human Naglu cDNA. This 
vector was designed to be used to transduce bone marrow stem cell ex vivo to be 
followed by transplantation into lethally-irradiated MPS IIIB. This approach is 
designed to evaluate the therapeutic outcome of the autologous HSC transduced 
with a lentiviral vector containing hNaglu on MPS IIIB mice. 
The human Naglu cDNA under the control of the CMV promotor (a gift from Dr. 
Elizabeth Neufeld) was used was subcloned by EcoRI digestion and subcloning into 
pBluescript II (pBKS) to create another BamHI restriction site at the 5’end of the 
Naglu insert. The BamHI fragment was was ligated 3’ of the human 
phosphoglecerate kinase (hPGK) promoter of a Lentiviral vector (LV) (a gift of Dr. 
Alessandra Biffi [17]) into which a BamHI linker had been inserted. (Fig.1).  
Materials and Methods 
The lentiviral vector was received from collaborators at the vector core of the 
Fondazione San Raffaele del Monte Tabor – Milano, Italy. The  vector has size of 
7840 bp, with a human phosphateglecerate Kinase promoter (hPGK), a self-
inactivating (sin) gene transfer construct (HIV), the Kanamycin resistance gene 
(KANA), the enhanced green fluorescent protein gene (eGFP), a polypurine tract 
and the termination sequences enhancing nuclear trans-location (PPT), a 
Mutated\Woodchuck\hepatitis\B\virus\Post-transcriptional Regulatory Element 
(MW/PRE), the cytomegalovirus promoter (CMV), and the Rev-responsive element 
(RRE) as a binding site for Rev protein with the viral RNA. A BamHI linker was used 
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to create a BamHI restriction site in the lentiviral vector to allow insertional cloning of 
the hNaglu-cDNA. The Naglu cDNA was in the pCMV plasmid under the control of 
Cytomegalao virus CMV promoter. The hNaglu-cDNA was shuttled into pBluescript 
II KS to introduce BamHI sites on both sides of the cDNA. This was followed by 
cloning of the cDNA into the Lentiviral vector. 
Results 
The efficiency of hNaglu cDNA cloning in the Lentiviral vector was evaluated by LRT 
sequencing using primers designed by Lasergene program and sequenced in Iowa 
State sequencing unit. The biological activity of the hNaglu cDNA Lentiviral vector 
was confirmed by the transfection of Human Embryonic Kidney 293 T (hEK) cells by 
the calcium phosphate Ca3 (PO4)2 transfection method. Naglu activity was detected 
in 1 ml DMEM media collected after hEK cells transfection 24hrs, 48 hrs, and 72 hrs 
(Fig 2). Naglu activity was also detected in the cell extract for the transfected hEK 
cells with the lentiviral vector after 72 hours. The positive control pCMV-hNaglu-
cDNA, and the negative control mock transfection hEK cells are shown in (Fig 3).  
Cre-Lox recombination system of conditional gene KOs 
The Cre-Lox recombination system is a site specific recombination system and is the 
most common technique used to generate a conditional gene KO mouse. This 
technique involves the targeted splicing of specific DNA sequences in the target 
gene. This is accomplished by an enzyme called Cre recombinase which consists of 
4 subunits and 2 domains. The splice sight is known as Lox P, isolated from 
bacteriophage P1, and consists of 34 pb [18]. 
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Subcloning of the MPS IIIC vector 
The pBY49a and pBLoxPa vectors were used for cloning the mouse HSGNAT gene. 
The HSGNAT gene is located on chromosome 8 and we cloned fragments which 
included exons 4 to 6 introduced as 3 fragments; A, B, and C. Two fragment of LoxP 
sites were inserted into the HSGNAT gene with the positive selection marker (an 
antibiotic resistance/selection gene; eg. Neomycin resistance gene or Neo) and a 
negative selection marker (Thmidine Kinase, TK) which was on the boundary 
between the HSGNAT gene and the vector. One LoxP fragment along with the TK 
gene was inserted between fragment B and C and cloned into pBLoxPa vector and 
the other LoxP fragment with Neo gene was inserted between fragment A and B and 
inserted in pBY49a vector (Fig 4). Plasmids pBY49a and pBYLoxPa were used to 
generate conditional KO ESC lines at the transgenic core at the University of Iowa. 
However this was an unsuccessful effort. By the time our initial homologus 
recombination attempts were conclude at the University of Iowa, HGSNAT 
embryonic clones became available from a European consortium of conditional 
transgenic mouse models, rendering further work in this area redundant on our part.
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Conclusions & Future Studies 
The combination of GT and HSCT can be used to improve the treatment for MPS 
IIIB and to this end we constructed a lentiviral vector containing the hNaglu-cDNA 
under the control of hPGK promoter. The lentiviral vector will be used in the future 
for ex vivo transduction of HSCT which will then transplanted into lethally irradiated 
MPS IIIB mice. Outcomes will be monitored by Naglu activity and GAG level in 
serum at different ages and also by post mortem biochemical and histopathological 
tissue analysis. 
Studying the single cell populations for function or loss thereof is a valuable tool to 
understand the pathogenic mechanism for genetic inherited diseases, e.g. the 
MPSs. However the conventional KO approach using homologous recombination in 
embryonic stem cell doesn’t allow for this type of research. Hence we pursued a 
conditional KO strategy Using a Cre-loxP recombination system and the HSGNAT 
gene (causative in MPS IIIC) we constructed of a plasmid suitable for homologous 
recombination. However after we this construction, alternative embryonic stem cell 
lines have been generated by European consortium rendering further work in this 
area redundant. 
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Figure1.  
A lentiviral 5’-3’hNaglu-cDNA plasmid construct-9569 bp with the transgene under 
the control of human PGK promoter. 
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Figure2.  
Transfection of 293 hEK cells by the calcium phosphate method. 
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Figure3. 
Transfection of 293 hEK cells using the calcium phosphate method. Naglu activity 
was measured in the cell extracts collected from a 6 well plate of the 293 hEK cells 
transfected with the LV, (right column), the pCMV-hNaglu (middle column), or mock 
transfected (left column. 
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Figure 4.  
Regions of the HGSNAT gene from exons 4-6, with fragments A, B, and C indicated.  
b) Methodology for cloning fragments A-C into pBY49a vector.  c) HGSNAT gene in 
murine embryonic stem cells (exons 4-6).  d) Homologous recombination between 
HGSNAT and targeting vector containing TK negative selection marker, neomycin 
positive selection marker, and FRT  and LoxP sites.  e) FRT sites flank neomycin 
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resistance gene.  When bred with FLPe mice, neocmycin resistance gene is 
removed.  f) LoxP sites flank exon 5.  When bred with Tissue Specific Cre Mice, 
exon 5 is removed (g). 
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CHAPTER 4: CONCLUSIONS AND DISCUSSIONS  
Conclusions 
There are many theoretical approaches to treat MPS IIIB which included ERT, HCT, 
GT, SRT, drug or small molecule therapy, and combinations thereof. Due to the 
rarity of this disorder, treatments require validation using animal models. But a 
greater challenge facing development of therapeutics is the delivery of the normal 
enzyme or gene across the BBB to the CNS, so that one can thereby treat the 
neurological symptoms of the disease. Also, MPS IIIB is often diagnosed by its signs 
relatively late. It has not been rigorously proven, but it is considered probable that 
CNS deficits, if present as they most often are at diagnosis, would respond poorly to 
therapy, in that a halt in progression may be the best outcome, with full resolution 
unlikely. It is quite likely that any fully or maximally effective treatment would require 
very early initiation, which would only be possible with routine neonatal screening. 
The intersection of development of therapy and of diagnostics is a troubling crux, in 
that large medical infrastructures cannot institute testing without a therapy, and 
development of a therapy is hampered by not having an optimal patient population to 
treat. 
Since there is at this time no successful treatment strategy which can stop the 
progression of or treat MPS IIIB disease, we aimed in this study to evaluate a 
potential treatment approach for MPS IIIB patients. Gangliosides play a crucial role 
in the development and function of the CNS [1]. However, the abnormal 
accumulation of gangliosides in the brain can lead to a group of diseases with 
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characteristic and severe brain degeneration. These diseases include those that 
store gangliosides as primary substrates of a missing enzyme, and those that 
accumulate gangliosides as part of a secondary response, the latter group of which 
includes MPS IIIB. The exact mechanism of this ganglioside triggered disease 
process and its relationship to ganglioside accumulation is not fully known at a 
mechanistic level. 
As mentioned above, Miglustat (Zavesca) is currently in use as a SRT 
treatment for non-neuropathic Gaucher disease. It limits the production of normal 
glycosphingolipids, so that the burden presented to the lysosome is at a level which 
can be degraded by any residual enzyme capacity, such that the burden of stored 
substrate is at a level below which one sees disease. Miglustat is a small 
iminosugar, and acts as a reversible inhibitor of glycosylceramide synthase, the 
enzyme responsible for catalyzing the first step of glycophospholipid synthesis. This 
drug can penetrate the BBB and reduce the accumulation of GM2 ganglioside in the 
CNS. It has minimal side effects relative to HCT or other potential therapies. 
Miglustat has been successfully used in Gaucher type I disease patients [2] and also 
in NPC disease patients who show improvement and stabilization in the clinical 
pathology accompanied in the CNS by reduced biosynthesis of glycosphingolipids 
including glucosylceramide and GM2 ganglioside [3]. In the case of MPS IIIB, the 
accumulation of GM2 ganglioside could potentially have a crucial role in MPS IIIB 
neuropathology. If this could be confirmed, substrate reduction therapy with 
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miglustat might be an effective treatment, limiting the disease’s neurological 
deterioration. 
This was the guiding motivation in our double knockout mouse approach. 
However the newly generated DKO MPS IIIB/GalNAcT mice model didn’t show any 
beneficial improvement in contrast to our expectations. In fact the total genetic 
elimination of GM2 ganglioside was striking in that it accelerated the clinical course 
of disease as well as the pathology. It bears mentioning that total genetic elimination 
of GM2, as we accomplished, might have been predicted to have untoward effects 
that simply limiting GM2 production to below some accumulation threshold may not 
have triggered. Regardless of theoretical speculations, since our study was initiated 
a human clinical trial of miglustat in MPS III patients was conducted, with the finding 
that there was not significant clinical benefit to miglustat therapy for MPS III [4]. 
While our model system offers little hope to GM2 targeted therapy in MPS III, 
the model system has led to findings with two major implications. First, the DKO 
animals have much more rapid clinical course with drastically shortened lifespans. 
This will allow researchers to study the pathogenesis of the disease and response to 
therapy in a much shorter time frame. The animals also succumb to a clear, rapid, 
and unambiguous clinical and humane end point. Second, this model has a unique 
pathological pattern of brain histopathology involving vacuolization of the white 
matter and neuropil. We feel, given some of the similar clinical findings in our end 
state DKO mice (urine retention), that this reflects accelerated MPS IIIB associated 
pathology and not just a novel pathology resulting from the genetic crosses used. 
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That this model may have utility as a means of testing future therapies is shown by 
our preliminary gene therapy treated DKO MPS IIIB/GalNAcT mouse, which showed 
extension in lifespan to nearly one year. 
Future studies 
The work presented herein is supportive of future study directions. First a rigorous 
and statistically significant study is required to extend the initial proof of principle 
work involving the DKO MPS IIIB/GalNAcT gene therapy treated mouse. However, it 
is critical to consider that even the treated DKO mice had a life span of only a year 
and didn’t reach a normal life span for the GalNAcT mice. This is suggestive of the 
need to evaluate very early, i.e. in utero, pathology in MPS IIIB, looking for evidence 
of HS storage during this period. If found, the possibility of in utero gene therapy is a 
viable one, to demonstrate if full and complete correction is possible using this 
model. 
Extending the brain histopathology analysis for the DKO MPS IIIB/GalNAcT 
mice is also warranted. Particularly by examining the brain at different ages with 
appropriate numbers of affected and control mice, it should be possible to find out 
whether the defects we see are in development, or if they represent a pathological 
cascade affecting normally developed white matter. Import also is better 
characterization of the white matter lesion which could involve transmission electron 
microscopy to assess axon number and myelination more quantitatively. This could 
better identify a primary white matter lesion, versus a neuronal lesion that leads to 
axon drop out.  
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There is an extant literature on the greater severity of MPS IIIA versus MPS 
IIIB. We did see in our model certain time points were the DKO IIIA versus DKO IIIB 
mice performed worse. A contemporaneous evaluation with larger numbers would 
be warranted to identify if this phenomena is reproducible and reflects some greater 
severity in MPS IIIA. The value of this finding might be in helping to identify 
significant pathological cascades. Gene expression networks that show early or 
greater changes in activity may help to focus a more hypothesis driven approach to 
investigating mechanisms. 
While we have argued that certain aspects of the clinical presentation of the 
DKO model (urine retention) are clearly associated with MPS IIIB, we cannot 
discount the possibility that some of the pathology of the DKO mice may be related 
to the GalNAcT null phenotype. It is important to age single knockout animals out to 
the natural humane end point and to examine brains histologically from these aged 
animals. This will allow us to conclude whether the DKO pathology is simply an 
accelerated form of some single knockout pathology (MPS IIIB or GalNAcT), or 
whether it is has unique characteristics. 
The extending the DKO MPS IIIB/GalNAcT mice model to generate a new 
DKO mouse model for MPS I/GalNAcT would be of enormous benefit on a number 
of fronts. First, MPS I is far more common a disease and the model could find 
application in proof of principle work which could affect very many more individuals. 
Second, MPS I is a HS storage disease as well, but with storage of dermatan sulfate 
that causes a great deal of orthopedic disease. This can complicate the assessment 
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of the mouse model when researchers wish to focus on the CNS disease. A model 
with rapidly accelerated disease of the CNS would be of great value. If an MPS I 
DKO mouse shows accelerated disease, the same could be expected for MPS II 
mice, which is a model of another more common neuropathic MPS disorder with HS 
storage. 
The lipid analysis by TLC method documented relatively higher levels of 
GM3, GD3, and O-acetylated GD3 gangliosides in the DKO MPS IIIB/GalNAcT mice 
brain relative to that of SKO GalNAcT mice brain. This provides some potential 
questions for investigations. There is an extant body of literature on the pathological 
effect of GD3 at the subcellular level. Investigation of subcellular storage of GD3 in 
storage diseases has never been undertaken. It is possible that secondary GM2 
accumulation has been a red herring, and that the pathological ganglioside is GD3. 
Furthermore, the effect of the O-acetylated GD3 is entirely unknown, and bears 
investigations as well, by both investigating whether it is a pathological accumulation 
and if so where is the effect, and by evaluating its potential biological effect. 
In summary, the newly generated DKO model could be a powerful system to 
use in the study of the pathogenesis of MPS IIIB disease and also to find appropriate 
treatment strategies. Also, this model system can be extended to the most common 
MPSs like MPS I disease to find an effective treatment for the children affected with 
this disease. 
  
97 
 
 
References 
[1] S. Chiavegatto, J. Sun, R.J. Nelson, R.L. Schnaar, A functional role for 
complex gangliosides: motor deficits in GM2/GD2 synthase knockout mice Exp 
Neurol 166 (2000) 227-234. 
[2] T. Cox, R. Lachmann, C. Hollak, J. Aerts, S. van Weely, M. Hrebicek, F. Platt, 
T. Butters, R. Dwek, C. Moyses, I. Gow, D. Elstein, A. Zimran, Novel oral treatment 
of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate 
biosynthesis Lancet 355 (2000) 1481-1485. 
[3] M.C. Patterson, D. Vecchio, H. Prady, L. Abel, J.E. Wraith, Miglustat for 
treatment of Niemann-Pick C disease: a randomised controlled study Lancet Neurol 
6 (2007) 765-772. 
[4] N. Guffon, S. Bin-Dorel, E. Decullier, C. Paillet, J. Guitton, A. Fouilhoux, 
Evaluation of Miglustat Treatment in Patients with Type III Mucopolysaccharidosis: A 
Randomized, Double-Blind, Placebo-Controlled Study J Pediatr (2011). 
 
 
98 
 
 
APPENDIX A: BIOCHEMICAL ANALYSIS TREATED ANIMAL 
MODELS 
Gene Therapy 
Gene Therapy is a technique used to deliver the genetic material into the cell to 
treat, prevent or slow the progression of genetic diseases using viral vectors or non-
viral vectors methods [1-4]. An adeno-associated viral vector (AAV) containing 
human Naglu has been evaluated in treatment of MPS IIIB mice by direct injection 
into the brain [5, 6] and this technique was extended to treat MPS IIIB dogs and 
evaluate the efficacy via biochemical assays of brain tissue. Direct injection of AAV-
hNaglu into the brain of MPS IIIB dogs was conducted to overcome and penetrate 
the blood brain barrier (BBB) and allow the delivery of the normal gene to the CNS. 
The AAV based vectors are very safe, small in size, and can accommodate a small 
cDNA such as hNaglu. These vectors can be produced in massive production and 
yield high viral vector concentration. They are non-integrating into the host genome, 
and elicit very mild immune response in the host. Furthermore, we need not 
transduce the whole brain since Naglu is easily secreted and taken up by the cells.    
Approaches and Techniques  
Evaluation of Naglu activity was done in brain samples from dogs described in the 
attached publication in this appendix. Assays used a fluorometric enzyme assay. 
Tissue processing was done by homogenization using the described buffer. Protein 
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concentration were measured by dye-based absorbance measurement [7] using a 
BCA protein assay Kit, and GAG assay was done using alican blue dye method [8]. 
History of Techniques  
Naglu Enzyme Assay Methods 
Naglu activity had detected by three different substrate techniques; colorimetric, 
radiometric and fluormetric assays. p-nitrophenyl-N-acetyl-α-D-glucosaminide was 
used in a Naglu colorimetric assay and the color chage was read using 
spectrophotometer at 436 nm (Von Figura K. & Kresse H., 1976). The Naglu enzyme 
activity has also been measured using a radiolabelled oligosaccharides substrate 
[9]. By far the most sensitive and practical approach however is the 4MU based 
fluorometric approach. 
Fluormetric methods 
Naglu activity was detected in MPS IIIB dogs brain extract by the fluormetric method 
using the fluorigenic substrate (4-methylumbelliferyl-α-N-acetylglucosaminide)- 2mM 
4-MU in water (50 µl), 0.2M acetate buffer, PH 4.3 (25 µl), and cell extract, which 
were then incubated for 4 hrs at 37 C. The reaction was stopped by adding 0.5 M 
glycine-NaOH buffer, PH 10.3 (1.5 µl) and fluorescence (excitation, 365 nm; 
emission; 450 nm) was measured by spectrofluorometer and enzyme activity was 
calculated as nanomoles of substrate hydrolyzed per hour per mg  protein [10].  
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Abstract 
Recent trials in patients with neurodegenerative diseases documented the safety of 
gene therapy based on adenoassociated virus (AAV) vectors deposited into the 
brain. Inborn errors of the metabolism are the most frequent causes of 
neurodegeneration in pre-adulthood. In Sanfilippo syndrome, a lysosomal storage 
disease in which heparan sulfate oligosaccharides accumulate, the onset of clinical 
manifestation is before 5 years. Studies in the mouse model showed that gene 
therapy providing the missing enzyme α-N-acetyl-glucosaminidase to brain cells 
prevents neurodegeneration and improves behavior. We now document safety and 
efficacy in affected dogs. Animals received eight deposits of a serotype 5 AAV 
vector, including vector prepared in insect Sf9 cells. As shown previously in dogs 
with the closely related Hurler syndrome, immunosuppression was necessary to 
prevent neuroinflammation and elimination of transduced cells. In 
immunosuppressed dogs, vector was efficiently delivered throughout the brain, 
induced α-N-acetyl-glucosaminidase production, cleared stored compounds and 
storage lesions. The suitability of the procedure for clinical application was further 
assessed in Hurler dogs, providing information on reproducibility, tolerance, 
appropriate vector type and dosage, and optimal age for treatment in a total number 
of 25 treated dogs. Results strongly support projects of human trials aimed at 
assessing this treatment in Sanfilippo syndrome. 
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Introduction 
Several recent human gene therapy trials for the treatment of neurodegenerative 
diseases relied on the deposit of adeno-associated virus (AAV) vectors directly into 
the brain. Results of phase I and phase II studies in Parkinson disease [1-3] and of 
phase I studies in pediatric neurodegenerative diseases [4, 5] indicated that this 
procedure is safe.  
Lysosomal storage diseases represent the most frequent cause of 
neurodegeneration in pre-adulthood. AAV-mediated direct gene transfer to the brain 
has been considered for the treatment of several neuropathic lysosomal storage 
diseases [6]. This approach is a particularly appropriate treatment option for most 
forms of Mucopolysaccharidosis type III (MPSIII, i.e., Sanfilippo syndrome). This 
disease is a heterogeneous condition caused by the deficiency of one of the 
lysosomal enzymes specifically required for the degradation of heparan sulfate 
glycosaminoglycans (GAGs) [7, 8]. Four genetic forms of MPSIII have been 
described. Type A (MPSIIIA, OMIM #252900), due to sulfamidase (SGSH; EC 
3.10.1.1) deficiency, and type B (MPSIIIB, OMIM #252920), due to α-N-
acetylglucosaminidase (NAGLU; EC 3.2.1.50) deficiency, are the most frequent. The 
accumulation of incompletely degraded GAGs in affected cells and tissues is the 
unique cause of cascades of pathological events. They include the secondary 
accumulation of gangliosides (GM2 and GM3), which possibly participate in 
neuropathology [9], and the progressive storage of intracellular vacuoles with 
lysosomal characteristics throughout the central nervous system [10]. Disease onset 
is before 5 years marked by hyperactivity and progressive mental impairment and 
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loss of social interaction. The severe neurological consequences of the disease are 
in stark contrast to the relatively mild somatic disease. By 10–15 years of age, 
affected children are disabled, often nonambulatory, requiring nutritional support, 
and in a semivegetative state. They often succumb to their disease in their mid-
teens. Correction of the enzyme deficiency in the brain and subsequent clearance of 
GAGs, GM2/GM3, and storage lesions will presumably prevent or reduce the most 
severe clinical manifestations of the disease. Indeed, AAV-mediated gene therapy in 
the brain of the mouse models of MPSIIIA [11] or MPSIIIB [12, 13] improved 
neuropathology and animal behavior. 
In order to translate proof-of-concept of efficacy from mouse models to 
human application, we previously explored AAV mediated gene therapy in the brain 
in seven dogs with MPSI [14], a disease closely related to MPSIII, in which a defect 
of the lysosomal enzyme α-iduronidase (IDUA; EC 3.2.1.76) interrupts the 
degradation of both heparan and dermatan sulfate [15]. MPSI (OMIM#607014) 
differs from MPSIII by severe skeletal involvement and by the relative efficacy of 
treatments based on hematopoietic stem cell transplantation [7, 8]. Therefore, MPSI 
is not as attractive a candidate for brain-directed AAV-mediated gene therapy as is 
MPSIII. The dog model of MPSI is nevertheless relevant for assessing tolerance and 
efficacy of gene therapy in a large animal developing MPS-related brain pathology. 
Herein, we describe completion of this treatment approach in 10 additional MPSI 
dogs, in which different treatment protocols were explored. Results reported here 
emphasize the efficacy and of vector type, vector dose, and age at treatment. 
107 
 
 
At the onset of AAV therapy evaluation in the MPSI dog, no large animal 
model of MPSIII was available. However, since that time a canine model has been 
identified and characterized for MPSIIIB [16], which we have used in the present 
study to assess the safety and efficacy of brain-directed AAV-mediated gene therapy 
for the treatment of children with MPSIIIB. Affected animals do not express clinical 
manifestations of the disease until ataxia occurs at late and varying age (18–30 
months). Like MPSI dogs, MPSIIIB dogs tolerated AAV mediated gene therapy well. 
Biochemical and pathological markers of the disease were improved in the entire 
brain of treated animals. We also confirmed that the combination of gene therapy 
with efficient immunosuppression was required for treatment efficacy. 
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Results 
Treatment protocol and tolerance 
The tolerance and efficacy of AAV-mediated gene therapy in the brain was assessed 
in 25 young adult dogs with MPSIIIB (n = 9), MPSI (n = 14), or not affected (n = 2). 
Analyses in MPSIIIB dogs were performed in 12.2–18.5-month-old animals. Studied 
animals belonged to three groups: untreated dogs (n = 3), dogs treated with the 
AAV2.5NAGLU vector without full immunosuppression (age at treatment: 9.5 and 
10.8 months, n = 2), and dogs treated with AAV2.5NAGLU vector and 
immunosuppression (age at treatment: 7.6–14.1 months, n = 7). The latter group 
included two dogs that received vector prepared in insect Sf9 cells using baculovirus 
vectors (B12 and B15). Analyses in MPSI dogs were performed in 4.2–16.0-month-
old animals. Studied animals belonged to four groups: untreated dogs (n = 5, 
including one dog that received immunosuppressant), dogs treated with the 
AAV5.5IDUA vector and immunosuppressant as young adults (age at treatment: 
3.4–4.8 months, n = 4, partial data on these dogs have been previously reported but 
are shown again to facilitate comparison with new animals that received different 
treatment protocols15), dogs treated with AAV2.5IDUA vector and 
immunosuppressant as young adults (age at treatment: 3.9–5.2 months, n = 6), and 
dogs treated with the AAV2.5IDUA vector and immunosuppressant at older age (age 
at treatment: 7.3–10.0 months, n = 4). Analyses of nonaffected dogs were performed 
at 1.6–17.0 months of age (n = 7). Studied animals belonged to two groups: 
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untreated dogs (n = 5), and dogs treated with the AAV2.5IDUA vector and 
immunosuppressant (age at treatment 3.6 and 3.8 months, n = 2).  
Treatment consisted of intracerebral deposits of AAV vector. The surgical 
procedure was similar in all treated dogs. It consisted of four stereotactic tracks with 
two 50-µl vector deposits at different depth per track (total volume 320 µl, flow 2 
µl/mn). The eight successive vector deposits necessitated animal anesthesia for 
about 4 hours. Surgery was well tolerated. Minor side effects were observed 
(hypotension, bradycardia, tachycardia, and hyperthermia), which were transitory 
and easily accommodated by anesthesia protocol adjustment. Animals experiencing 
this episode had not significant postoperative issues. Transient diminution of 
palpebral reflexes, fever and unstable blood pressure, and respiration frequency, 
which spontaneously reversed after 2–3 days, were observed in three animals. One 
dog (B99) with a suspected hemostatic disorder not related to MPSIIIB after a 
completely unremarkable surgery experienced semiparesis and proprioceptive 
deficit that were fully resolved at 1 month.  
Based on our previous observations, the administration of 
immunosuppressant (a combination of cyclosporine and mycophenolate mofetil) was 
mandatory to prevent immune response against the therapeutic enzyme in MPSI 
dogs.15 Immunosuppression was associated with frequent side effects, including the 
development of papillomas (13 dogs, 52%), gingivitis (4 dogs, 16%), diarrhea (19 
dogs, 76%). Disability resulting from papillomas necessitated euthanasia in five 
MPSI dogs with severe skeletal manifestations of the disease. Reactions to 
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immunosuppression had less severe consequences in MPSIIIB dogs (papillomas in 
three dogs), which appeared healthy at the time of treatment and during follow-up.  
Treated MPSIIIB dogs were killed after 3.7–4.4 months. The duration of 
follow-up of treated MPSI dogs was determined by the health status and varied from 
0.7 to 8.3 months. Brain tissue was investigated to assess gene transfer efficiency 
and treatment efficacy. Analyses consisted of vector genome (vg) quantification by 
quantitative PCR (qPCR), assay of therapeutic enzyme activity, dosage of primary 
and secondary storage products (GAG, GM2 and GM3), and histopathology 
examination. Storage lesion density was determined on histological sections stained 
by hematein–eosin or luxol fast blue in order to provide an exhaustive view of 
pathology throughout the brain. A semiquantitative scoring system (0 indicating the 
absence of lesion, with 3 indicating severe pathology) was used for cerebrum and 
cerebellum. The number of luxol-positive storage lesions was determined in a 
defined surface area of the caudate nucleus. Results are summarized in Table 1, 
shown in Figures 1–4, and commented upon below. 
AAV genome delivery 
Efficient treatment of neuropathology in lysosomal storage diseases supposes broad 
vector delivery to brain tissues. We previously showed in MPSI dogs (D6, D7, D8, 
and D9) that AAV5 capsids allow delivery of vg to large portions of the brain [15]. We 
confirmed these findings in the additional MPSI dogs enrolled in the present study 
and showed a similarly efficient spreading of the AAV2.5NAGLU vector in the brain 
of MPSIIIB dogs (Table 1 and Supplementary Figure S1).  
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The proportion of brain tissue samples in which vg were detected by qPCR 
did not significantly differ between treated MPSI, MPSIIIB, and normal dogs (Figure 
1a, P = 0.057). We nevertheless noticed that vg were more frequently detected in 
the most caudal brain sections in MPSIIIB than in MPSI dogs. Vector distribution did 
not differ between MPSI dogs treated with AAV5.5IDUA or AAV2.5IDUA vectors 
(Figure 1a, P = 0.32), and when the AAV2.5IDUA vector was injected in young or 
older MPSI dogs (Figure 1b, P = 0.136).  
All dogs received a total vector dose of 5 × 1011 vg, with three exceptions 
(D16, D17, and D23). The quantification of vg copy numbers in brain tissue showed 
large variations depending on the animal (Supplementary Figure S1). Maximal 
values ranged from 81 to 3,289 genome copies/cell in MPSI dogs and from 52 to 
2,480 genome copies/cell in MPSIIIB dogs, without significant difference between 
these groups. Very low genome copy numbers were detected in B54 (<1 genome 
copy/cell), a MPSIIIB dog that did not receive immunosuppressant. Genome copy 
numbers were also low in B89 (maximal value 39 genome copies/cell), a MPSIIIB 
dog in which immunosuppression was halted 2 months before sacrifice due to digital 
papillomatosis. The highest vg copy numbers among treated MPSIIIB dogs were 
measured in the two animals that received vector prepared in Sf9 cells, indicating 
that this preparation method generates particles capable of efficient penetration of 
target cells. Whereas vg copy number in D16 (dose: 8 × 1011 vg, maximal value 109 
genome copies/cell) and D23 (dose: 20 × 1011 vg, maximal value 602 genome 
copies/cell) did not differ from the mean value in dogs treated with the standard dose 
(5 × 1011 vg, maximal value 477 ± 261 genome copies/cell), significantly higher 
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copy numbers were measured in D17 (dose 21 × 1011 vg, maximal value 1,603 
genome copies/cell, P = 0.001, one-sample t-test). 
Disease correction in MPSIIIB dogs 
When compared to non-affected animals, pathology in the brain of 1-year-old 
untreated MPSIIIB dogs was characterized by high levels of GAG, GM2/GM3 
gangliosides, high scores in semi-quantitative scoring of storage lesions, and a high 
density of quantitatively measured luxol-positive storage lesions in the caudate 
nucleus (Table 1 and Figures 2–4).  
As previously observed for IDUA delivery in the brain of MPSI dogs [15], 
NAGLU was detected in large parts of the brain in treated MPSIIIB dogs that 
received immunosuppression (>70% in four out of the five dogs in which analysis 
was performed (Table 1 and Supplementary Figure S2). However, NAGLU activity 
remained low or undetectable in the most rostral and most caudal regions of the 
brain (especially in the cerebellum). Surprisingly, certain distal areas in which 
NAGLU was not detected contained vg, as shown by qPCR, suggesting that 
catalytic activity was too low for detection by the enzyme assay, the sensitivity of 
which is actually poor (≥0.1 U/mg of protein).  
All pathology markers were improved in MPSIIIB dogs that received 
immunosuppression, in comparison to untreated MPSIIIB dogs (Table 1 and Figures 
2 and 3). However, values remained higher than in nonaffected dogs (GAG, P = 
0.003; GM2, P = 0.048; GM3, P = 0.005; storage lesions in the caudate nucleus, P = 
0.018, Figure 2). Moreover, storage lesions persisted unchanged in the cerebellum 
and were partially and inconsistently improved in the meninges (Table 1).  
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Consistently with our previous observations in treated MPSI dogs that 
received low immunosuppressant regimen [15], NAGLU activity was not detected in 
the brain of two dogs (B54 and B89) that did not receive full immunosuppressant 
regimen (Table 1 and Supplementary Figure S2). In B54, which never received 
immunosuppressant, GAG levels and storage lesions were comparable to untreated 
MPSIIIB dogs. GM2 and GM3 accumulations were nevertheless significantly 
reduced (Table 1, P = 0.012 and P = 0.018, respectively, one-sample t-test). 
However, pathology was not corrected and intense inflammation was observed in 
the thalamus (Figure 3). In B89, which received immunosuppressant for 2 months 
followed by 2 months without immunosuppressant, GAG (P = 0.048), GM2 (P = 
0.015), GM3 (P = 0.022), and storage lesions in the caudate nucleus (P = 0.032, 
one-sample t-test) were significantly reduced, as compared to untreated MPSIIIB 
dogs. However, inflammation was prominent in the thalamus, perivascular spaces 
were infiltrated with macrophages, and storage lesions were unchanged as 
compared to untreated MPSIIIB dogs in the frontal and occipital cortex. These 
results confirmed that immunosuppression was mandatory to preventing 
inflammatory response and allowing disease correction in the brain of treated 
MPSIIIB dogs. 
Disease correction in MPSI dogs 
When compared to non-affected animals, pathology in the brain of untreated MPSI 
dogs was marked by high levels of GAG, GM2/GM3 gangliosides, high scores in the 
semi-quantitative scoring of storage lesions, and high density of luxol fast blue 
positive storage lesions in the caudate nucleus (Table 1 and Figures 2 and 3). When 
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comparing approximately age-matched animals (7–12 months), GAG storage and 
GM3 accumulation were more marked in MPSIIIB than in MPSI dog (Figure 2, P = 
0.036 and P = 0.053, respectively).  
With the exception of one dog (D29), all pathology markers were improved in 
MPSI dogs treated at early stage of the disease. Values were not significantly 
different between MPSI dogs treated with AAV5.5IDUA or AAV2.5IDUA (Table 1 and 
Figure 2). However, considering these two groups of treated MPSI dogs together, as 
observed for treated MPSIIIB dogs, values remained higher than in non-affected 
dogs, indicating persistent low level of GAG storage (P = 0.005), GM2/GM3 
ganglioside accumulation (P = 0.001 and P = 0.040) and storage lesions in the 
caudate nucleus (P = 0.003). Storage lesions persisted in the cerebellum and were 
only partially improved in the meninges (Table 1).  
One animal (D29) showed a contrasting result. Whereas histology was not 
improved compared to untreated MPSI dogs (Table 1 and Figure 3), GAG, GM2, 
and GM3 values were lower than in untreated MPSI dogs (Table 1, P < 0.001, P = 
0.015, P = 0.011, and P = 0.011, respectively, one-sample t-test). We assume that 
this dissociated phenotype was related to the short delay between treatment and 
analysis (0.7 months).  
Noticeably, whereas disease correction was fully effective in MPSIIIB dogs 
treated between 7 and 14.1 months of age, markers of pathology were either not 
improved or only partially improved in MPSI dogs that received treatment after the 
age of 7 months, especially with regards to histological lesions (Table 1 and Figure 
3). In D15, which was treated at 8.9 months and analyzed shortly after (1.3 months), 
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biomarkers and histology did not show improvement as compared with untreated 
MPSI dogs. In D17, which was treated at 10 months and followed up for 6 months, 
biomarkers were improved but histology indicated major residual lesions. In D16 and 
D25, which were treated at 7.3 and 8.3 months and followed up for 4.4 and 1.8 
months, respectively, biomarkers were normalized, residual lesions were minimal in 
the caudate nucleus, but storage lesions persisted at other locations. 
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Discussion 
We report herein on a comprehensive study of 25 adult dogs that underwent AAV-
mediated direct gene therapy in the brain and 13 untreated control dogs. This study 
extends and confirms our previous conclusions about the safety and efficacy of this 
treatment in dog models of MPS [15]. We provide evidence for tolerance and 
phenotypic improvement in MPSIIIB, a disease that represents a good candidate for 
clinical evaluation of gene therapy. Results obtained in the two investigated dog 
models are fully consistent. The high number of animals that were safely and 
successfully treated emphasizes the reproducibility of the procedure and its 
suitability for human application. 
AAV vector delivery to the brain 
Efficient spreading of vector particles in the brain is crucial for the treatment of 
diseases like many of the MPSs in which pathology is widespread in the central 
nervous system. We previously showed in mice [13], dogs [15], and monkeys [17] 
that surgical deposits of AAV5 vectors particles in the brain ensures efficient 
spreading of vg throughout the cerebrum. These observations were fully confirmed 
in the present study performed in a large number of dogs. Results showed that after 
eight deposits of AAV5 particles in the brain through four stereotactic tracks, the 
average proportion of the dog brain in which vg were detected was in the range of 
85%. Eight dogs showed vg at all investigated territories. Similar spreading was 
observed when AAV2 or AAV5 genomes were packaged in AAV5 particles. Two 
dogs that received a fourfold higher vector dose were positive throughout the brain, 
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but only one showed higher mean vg copy numbers than the mean value in the 23 
animals treated with the regular dose of 5 × 1011 vg, suggesting that the efficiency 
of vector delivery to brain tissues was not strictly related to the amount of deposited 
vector particles. For the same vector batch, vg copy numbers in tissues were 
actually highly variable depending on the animal and the examined brain territory. 
The analysis of two normal dogs, which received the AAV2.5IDUA vector and were 
followed up for ~1 year, indicated that high-vector copy number and widespread 
distribution in the brain persisted over the long term.  
Vector particle deposition was well tolerated. Examination of injection sites at 
various time points after vector deposition (from 3 weeks to 13.5 months) did not 
reveal, in the presence of concurrent immunosuppression, either persistent local 
inflammation, or sequel of inflammatory reaction, even in the animals that received 
the highest vector dose (2 × 1011 vg at each deposit site). Thus, a deposit of 2 × 
1011 vg was well tolerated. This finding is important when discussing the adequate 
vector dosing for treating human patients. Vector tolerance was equally good and 
spreading equally efficient in the two MPSIIIB dogs that received vector particles 
produced in insect cells using baculovirus vectors, as compared to dogs that 
received AAV vector prepared by co-transfection of human embryonic kidney 293 
human cells with plasmid DNA. The AAV vector production method based on the 
use of baculovirus vectors to deliver packaging components to Sf9 cells is well 
adapted to large scale manufacturing processes required for clinical batches 
preparation [18]. Our results indicate that this method of production should be 
considered for human trials. 
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Disease correction 
MPSI or MPSIIIB dogs do not express clinical manifestations of central nervous 
system disease at the ages animals were treated and followed-up. Whereas ataxia 
occurs at advanced stage of the disease in MPSIIIB dogs, animal age at onset is not 
a reliable clinical marker because of major variations among affected animals and of 
the absence of an appropriate description of the natural history of the canine 
disease. Life span, which depends on the affection of peripheral organs in MPSI 
dogs and of humane decision in MPSIIIB dogs developing ataxia, is also not an 
adequate clinical marker. We therefore relied on biochemical markers (GAGs and 
GM2/GM3 levels) and histological markers to assessing disease severity in dog 
brain. As pathology associated to MPSI and MPSIIIB is spread throughout the 
central nervous system, these markers were investigated in the entire brain using 
adequate methodologies.  
Biochemical and histological markers were consistently improved in the 
almost entire brain in all treated dogs that received immunosuppressant (16 dogs). 
Improvement of biochemical markers with persistent histological lesions was 
observed in few dogs, D29 which was examined early after treatment (0.7 months), 
three MPSI dogs that were treated after the age of 7.3 months of age (D16, D17, 
D25), and two MPSIIIB dogs that did not receive immunosuppressant (B54, B89). 
These results suggest that clearance was more rapid and more easily obtained for 
stored products than for storage lesions. We do not know which of these markers is 
the most relevant to clinical manifestations in children. With respect to future 
therapeutic trials, GAG and GM2/GM3 ganglioside concentrations in the 
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cerebrospinal fluid (CSF) represent potential surrogate markers of pathology severity 
in the brain, and therefore potential end points for the assessment of treatment 
efficacy in human trials. The observation of a possible dissociation between 
biochemical and histological markers emphasizes the importance of considering 
clinical end points in complement to biomarker assays on CSF to assess treatment 
efficacy in children.  
Although biochemical and histological markers were consistently improved in 
16 treated dogs that received immunosuppressant, treatment did not result in the 
complete resolution of disease-associated storage in the brain. Whereas GAG and 
GM2/GM3 gangliosides levels were close to normal values, they remained elevated 
relative to those of normal dogs, and residual histological lesions persisted. We do 
not know whether this residual disease will result in clinical symptoms in treated 
children. Treatment efficacy was also limited by the lack of improvement in the 
cerebellum, which was consistent with the almost total absence of vg in this tissue. 
We presume that an additional local vector deposit will be necessary to treat 
cerebellar disease and associated signs in children.  
The age of MPSI dogs at the time of treatment affected efficacy. The four 
MPSI dogs treated after the age of 7.3 months showed either no improvement 
(D15), improvement of biological markers only (D17), or improvement of biological 
markers and histological lesions near vector deposition sites but not at distant 
locations (D16 and D25). These results may represent an age corollary in the canine 
model to young severely affected MPSI patients, where it is recognized that 
hematopoietic stem cell transplantation is not efficacious for patients older than 24 
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months [8].  In contrast, MPSIIIB dogs responded fully to treatment when treatment 
was initiated at 9.2 ± 2.2 months. This result suggests different kinetics of disease 
progression may apply to canine MPSI and MPSIIIB. 
Immunosuppression 
A major determinant of treatment safety and efficacy was immunosuppression. 
Confirming our previous observations in MPSI dogs that received low 
immunosuppressant regimen [15], we show that absence (B54), or interruption (B89) 
of immunosuppressant in MPSIIIB dogs resulted in low vector copy numbers, 
absence of detectable NAGLU activity in brain extracts, almost unchanged 
pathology severity and marked inflammatory reaction. These results unambiguously 
indicate that effective immunosuppression will be mandatory for treatment safety 
and efficacy in children. Immunization against the therapeutic recombinant enzyme 
is frequent in children receiving enzyme replacement therapy, including in patients 
with residual enzyme activity [19].Thus, the synthesis of a mutant protein does not 
necessarily induce tolerance to the wild type molecule. We previously showed that 
the immune response was directed against both the vector components and the 
therapeutic enzyme IDUA in treated MPSI dogs [15]. We therefore presume that a 
similar reaction occurred against NAGLU in treated MPSIIIB dogs. However, the 
presence of anti-NAGLU antibodies in treated dog brain extracts could not be 
documented because antibodies are not available to designing appropriate assays. 
Low vg copy numbers in dogs that did not receive immunosuppressant is consistent 
with the immune elimination of transgenic cells. Interestingly, the improvement of 
biological markers in B54 and B89 suggests that transient delivery of the therapeutic 
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enzyme preceding immune reaction might have been sufficient to clear primary 
storage products (GAGs), at least partially and transiently. 
This extensive study in dogs provides large animal validation for a treatment 
of central nervous system manifestations of MPSI and MPSIIIB in affected children 
using AAV-mediated gene therapy directed to the brain. Patients with MPSIII 
represent the group of neuropathic MPS patients with the most urgent need for an 
effective treatment that targets the brain. Indeed, in contrast to MPSI, MPSIII does 
not appear to be improved by hematopoietic stem cell transplantation and is not 
associated with severe peripheral manifestations. The devastating natural course of 
this disease may mitigate consideration of such an approach to therapy, in spite of 
the known or potential and unforeseeable risks of gene therapy, in addition to the 
well-documented risks of immunosuppression. 
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Materials and Methods 
AAV vector structure, construction, and production 
The structure of the AAV5.5-hIDUA vector was previously reported [20]. Briefly, this 
vector contains the murine phosphoglycerate kinase (pgk) gene promoter, the 
human complementary DNA (cDNA) coding for IDUA, the woodchuck 
posttranslational response element and the bovine hormone polyadenylation site. 
The AAV2.5-hIDUA has a similar structure in an AAV2 backbone. The AAV2.5-
hNAGLU contains the murine phosphoglycerate kinase gene promoter, the human 
cDNA coding for NAGLU and the bovine hormone polyadenylation site, but does not 
contain woodchuck post-translational response element. Vector production in human 
embryonic kidney 293 cells was performed as previously described [20].  
For production in Sf9 cells, the human NAGLU cDNA was previously cloned 
into a pUC-derived plasmid, pKAAV-PGK-hNAGLU-pA, which contains the hNAGLU 
cDNA under the control of the mouse PGK gene promoter and the bovine hormone 
polyadenylation site. The fragment containing the ITR and the hNAGLU expression 
cassette was cloned into the pPSC10 transfer plasmid (Protein Science, Meriden, 
CT). The sequence of the final clone was verified by DNA sequencing. A 
recombinant hNAGLU baculo virus (BAC-hNAGLU) was generated by co-
transfection of Sf9 cells with the pPSC10-hNAGLU transfer plasmid and the 
linearized polyhedron gene-deficient AcNPV virus genome. Titration and integrity 
testing of BAC-hNAGLU was performed by qPCR. The rAAV5-hNAGLU vector was 
produced by triple-infection of Sf9 cells with BAC-Rep, BAC-Cap5 and the BAC-
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hNAGLU, as described [18]. Seventy-two hours before infection, baculovirus stock 
was amplified by infection of Sf9 cells. Seventy-two hours Post infection, Sf9 cells 
were counted to determine the percentage of viability, and were harvested by 
centrifugation (1,900g for 15 minutes at 4 °C). Cells were lysed at 28 °C for  1 hour 
under agitation and then treated with Benzonase (Merck, Lyon, France) for 1 hour at 
37 °C. Supernatant was clarified by centrifugation at 1,900g for 15 minutes at 4 °C 
and further purified by affinity chromatography using AVB Sepharose High-
Performance affinity medium (GE Healthcare, Velizy, France). A second purification 
step was added using a discontinuous iodixanol gradient protocol as previously 
described [21]. The fraction containing the higher quantity of vg (determined by 
qPCR) was ultrafiltrated trough Vivaspin 15 centrifugal tubes (30000 MWCO; 
Sartorius Stedim, Aubagne, France) and diafiltrated. The final product was 
formulated in a solution of phosphate-buffered saline with 5% sucrose. 
MPSIIIB dogs 
The canine model of MPSIIIB has been previously described [16]. All animal studies 
involving MPSIIIB were conducted at Iowa State University and followed both 
National Institutes of Health and United States Department of Agriculture guidelines 
for the care and use of dogs in research. All protocols were conducted according to 
protocols reviewed and approved by the Iowa State University IACUC committee. 
Heterozygous and affected MPSIIIB breeders were used to produce affected 
MPSIIIB dogs. Dogs were diagnosed at birth by a PCR assay for the mutant NAGLU 
allele. The natural history of the disease in these dogs is such that animals are 
apparently healthy until 18–30 months, after which they progressively develop 
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severe ataxia. This dog colony carries an additional genetic defect (von Willebrand 
deficiency), that is unrelated to MPSIIIB and which was identified after the first three 
dogs were treated (B54, B77, and B99). Subsequent animals were tested to confirm 
their nonaffected status with regard to von Willebrand factor. 
MPSI dogs  
Heterozygous MPSI breeders were obtained from Dr E. Kakkis (BioMarin Pharm, 
Novato, CA) and Dr H.P. Kiem (Fred Hutchinson Cancer Research Center, Seattle, 
WA). Dogs carrying the recessive mutation underlying canine MPSI [22] were bred 
at the Centre de Boisbonne of the National Veterinary School of Nantes. 
Homozygous puppies (MPSI dogs) were diagnosed at birth by IDUA assay showing 
the absence of detectable activity in peripheral blood lymphocyte extracts. Clinical 
symptoms of MPSI were noticed soon after birth in most severely affected dogs and 
before 3 months of age in all MPSI dogs. Symptoms included corneal clouding, 
facial dysmorphism, dysostosis multiplex, umbilical hernia, liver failure, and 
holosystolic cardiac murmur. The Institutional Animal Care and Use Committee of 
the National Veterinary School of Nantes and the University of Nantes approved 
experiments, which were performed by authorized investigators. 
Surgery  
MPSI dogs were anesthetized with a combination of medetomidine (Domitor; Pfizer, 
Paris, France), morphine (Morphine; Aguettant, Lyon, France), and ketamine 
(Imalgène; Merial, Villeurbanne, France) given intravenously as induction drugs. 
After endotracheal intubation, anesthesia was maintained with 1.5% isoflurane. For 
MPSIIIB dogs, anesthesia consisted of isoflurane inhalation (3% vol/vol) and 
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morphine injection (0.1 mg/kg). Dogs were monitored by clinical observations, 
respiratory rate measurement, temperature measurement, electrocardiography, 
pulse oximetry, and capnography. Vector was deposited at two locations (four 
deposits) in each brain hemisphere during a single session. Tracks targeted the 
putamen and the centrum semiovalae (0.2 mm rostral and 10 mm caudal, 
respectively, 15 mm lateral to the bregma, depth 10 and 20 mm). All treated animals 
received the same vector suspension volume (8 × 40 µl) at the same injection flow 
(2 µl/minute). Amounts of deposited vector depended on vector concentrations in the 
deposited suspension (5 × 1011 vg, 1.5 × 1012 vg/ml; 8 × 1011 vg, 2.5 × 1012 
vg/ml; 20 × 1011 vg, 6.5 × 1012 vg/ml). No immediate or early severe side effect 
presumed to be directly related to surgery or vector deposits was noticed. 
Immunosuppression  
Immunosuppressants consisted in the combination of mycophenolate mofetil (800 
mg/m2/day) and a weekly-adjusted dose of cyclosporine to maintain 
cyclosporinemia >300 ng/ml. 
Tissue processing 
MPSI dogs were killed by over anesthesia when they become unable to stand on 
their legs or stop taking food. MPSIIIB dogs were killed ~4 months after surgery. 
Anesthetized animals were perfused with 150 ml of phosphate-buffered saline and 
600 ml of 4% paraformaldehyde in phosphate-buffered saline. Brain hemispheres 
were immediately cut into 4-mm thick coronal slabs (n = 15–17). Every third slab 
was used for vg and NAGLU or IDUA activity detection, GAG and ganglioside 
assays, and histology, respectively. Slabs used for genome detection and enzyme 
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assays were divided in dorsal lateral, dorsal median, ventral lateral, and ventral 
median quarters. Each quarter was cut into ~100 mg fragments, which were 
submitted to three freeze-thaw cycles after the addition of water (200 µl). DNA was 
extracted from nuclear pellets, and pools corresponding to each entire quarter were 
used for qPCR. Pools of supernatants were similarly used for enzyme assay. We 
usually recovered in the range of 40 µg of DNA and 15–20 mg of protein/gram of 
tissue. Much lower values suggested that tissue fixation had been too intense to 
allow efficient extraction and did not allow reliable vector detection (B63, B71), or 
enzyme assay (D29, D30, D31, D33, D37, B63, B71). For GAG and gangliosides 
assays, four samples were analyzed for each dog brain. Each sample consisted in 
the mixture of two slabs (two rostral left, two rostral right, two dorsal left, and two 
dorsal right). Values indicated in Table 1 and Figure 2 are means ± SEM of the four 
measured values. 
Determination of vg copy numbers by qPCR analysis 
Sequences from the human NAGLU cDNA, the human IDUA cDNA and the canine 
β-glucuronidase gene were amplified. Vg copy numbers were determined by qPCR. 
Sequences from the human NAGLU cDNA or human IDUA cDNA were amplified 
using either SyberGreen (D6, D7, D8, D9), or Taqman (other dogs) qPCR methods. 
Equivalent efficiency of the Taqman and SyberGreen methods was previously 
documented in this context [15]. Reference curves were established by determining 
cycle threshold (Ct) values for the amplification of serial dilutions of plasmid DNA 
containing the human NAGLU [23] or IDUA [24] cDNA (38–6 × 105 copies). The 
same sequences were simultaneously amplified from serial dilutions of dog brain 
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genomic DNA (0.156–50 ng of DNA/reaction). Vg copy numbers were calculated for 
every Ct according to reference curves and expressed for 2N genomes according to 
measured canine β-glucuronidase gene copy numbers. Primers and probes: human 
NAGLU cDNA, 5′-CAGTGCTGCCTGCATTCG-3′ (forward), 5′-
GTGACATTGACCTGCATTCG-3′ (reverse), 5′-FAM-
TTCCCGAGGCTGTCACCAGG-TAMRA-3′ (probe); human IDUA cDNA, 5′-
ACTTGGACCTTCTCAGGGAGAAC-3′ (forward), 5′-
CACCTGCTTGTCCTCAAAGTCA-3′ (reverse), 5′-FAM-
CAGCGCCTCGGGCCACTTCA-TAMRA-3′ (probe); canine β-glucuronidase gene 
exon 9, 5′-ACGCTGATTGCTCACACCAA-3′ (forward), 5′-
CCCCAGGTCTGCTTCATAGTTG-3′ (reverse), 5′-FAM-
CCCGGCCCGTGACCTTTGTGA-TAMRA-3′ (probe). Amplification parameters were 
as previously described [15]. The assay sensitivity threshold was 0.1 copies per 
diploid genome. 
α-N-acetyl glucosaminidase and α-l-iduronidase assays 
NAGLU and IDUA assays were performed as described [25, 26]. Tissue was 
homogenized in water, submitted to three freeze/thaw cycles and centrifuged at 
13,000 r.p.m. for 3 minutes. Detection threshold enzyme activity in tissue extract 
was 0.1 U/mg of protein. 
Histology 
Neuropathology was assessed on full-hemisphere coronal slabs that had been fixed 
in 4% paraformaldehyde, embedded in paraffin, and cut into 4-µm sections. In 
treated dogs, sections were prepared from slabs adjacent to those in which vg and 
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IDUA or NAGLU were assayed, providing information about gene and enzyme 
delivery at the examined locations. Sections were stained either with hematoxylin–
eosin for semiquantitative analyses or with periodic acid-Schiff APS and luxol fast 
blue associated to Bodian’s silver impregnation for quantitative analysis of residual 
lesions. 
Storage lesions quantification 
Semiquantitative analyses were performed in four neuroanatomic areas (frontal 
cortex, caudate nucleus, thalamus, and occipital cortex). Lysosomal distension was 
scored according to the percentage of vacuolated cells (absence = 0; presence in up 
to 20% of the cells = 1; up to 50% = 2; >50% = 3). For quantitative analysis of 
storage lesions, neuronal profiles were scored as positive when their cytoplasm 
contained luxol-stained granules. A 97.7% scoring reliability was measured using 
materials from five untreated MPSI dogs. Lesions were not detected in non-affected 
dogs. 
Analysis of gangliosides 
Samples were homogenized with a minimum volume of water (10% vol./weight). 
Total lipids were extracted from water homogenates [27] isolated and desalted using 
reverse-phase Bond Elut C18 columns (Varian, Buc, France) [28]. Gangliosides 
were separated on G60 high-performance thin-layer chromatography plates (Merck), 
visualized by resorcinol/HCl and quantified by densitometry. Data (mean of 
duplicates) were expressed as molar percentage of total gangliosides. 
GAG assay 
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Frozen samples were homogenized with a minimum volume of water (10% 
vol./weight). Defatted pellets were dried and weighed. Dried residues were digested 
overnight at 65 °C with papain (0.3% wt.:vol.) in 3  ml of 100 mmol/l sodium acetate 
buffer pH 5.5 containing 5 mmol/l cysteine and 5 mmol/l EDTA. After centrifugation, 
GAGs were measured in the supernatant with a dimethylmethylene blue dye-binding 
assay. Briefly, 200 µl of the supernatant was added to 2.5 ml of dimethylmethylene 
blue reagent [29] and the absorbance at 535 nm was measured. Heparan sulfate 
(H7640; Sigma-Aldrich, St Quentin-Fallavier, France) was used as standard. Data 
(mean of duplicates) were expressed as µg of GAGs per mg of dried pellet. 
Statistical analysis 
Statistics were performed using the SPSS software (SPSS). The assumption that 
the values follow normal distribution was verified by the Shapiro–Wilk’s test. 
Indicated P values were calculated using Student’s t-test, except when specified 
otherwise. 
Supplementary material  
Figure S1. Spreading of AAV vectors in treated dog brains. 
Figure S2. Spreading of IDUA or NaGlu activity in treated dog brains. 
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Table 1.  
Overview of investigated dog groups, treatment conditions, and disease markers. 
Abbreviations: AAV, adeno-associated virus; IDUA, α-iduronidase; MPSIII, 
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mucopolysaccharidosis type III; NAGLU, α-N-acetylglucosaminidase; ND, not 
determined. This table provides information about the severity of the disease (Cli. 
exp.: A, absent; M, moderate; S, severe), the age (in months, mo) at treatment (age 
inject.), the age at euthanasia (age anal.), the duration of follow-up (follow-up), the 
injected AAV vector type (AAV vector type, asterisks indicate the two dogs that 
received vector prepared in Sf9 cells, B12 and B15), the total amount of vector 
genomes deposited in the brain (Vect. dose), the immunosuppressive treatment (IS), 
the proportion of brain fragments in which >0.1 vector genome copy was detected 
(Genome % frag. > 0.1 copy), the proportion of brain fragments in which >0.1 unit of 
IDUA (MPSI dogs) or NAGLU (MPSIIIB dogs) per mg of protein was measured 
(Enzyme % frag. > 0.1 U), the mean values of GAG, GM2 and GM3 assays (4 
determinations per dog, SEM are omitted here for clarity and shown in Figure 2), the 
mean of the semiquantitative pathology scores determined at four locations (frontal 
cortex, occipital cortex, thalamus and caudate nucleus) in the brain (mean path. 
score brain, SEM are omitted here for clarity and shown in Figure 2), the 
semiquantitative pathology score determined in the cerebellum (mean path. score 
cereb.), the semiquantitative pathology score determined in the meninges (mean 
path. score menin.), the number of luxol fast blue positive lesions scored in a 
predefined area of the caudate nucleus (Lesions luxol + caud. Nucleus). NA: not 
available. For genomes and enzyme (D30, D31, D33, D37, D29, B63, B71) missing 
values are due to inappropriate tissue fixation (see Materials and Methods section). 
For pathology score in the cerebellum (B89), the missing value is due to the lack of 
fragment with cerebellar tissue. 
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Figure1.  
AAV vector genome spreading in dog brains. MPSI or MPSIIIB dogs received AAV-
mediated gene therapy and immunosuppressive treatment. Brains were cut in 4–8 
coronal slabs, which were further divided in four fragments, producing 16–32 
fragments per dog brain. Copy numbers of the endogenous β-glucuronidase gene or 
AAV vector genomes were determined by quantitative PCR in DNA extracted from 
each fragment. The ratio of these two values indicates the number of vector genome 
copies/cell. Supplementary Figure S1 shows the distribution in the brain of 
fragments containing >0.1 vector genome copies/cell. (a) Histograms indicate the 
proportion of brain fragments in which >0.1 vector genome copy/cell was measured 
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in each group of treated dog: MPSI dogs treated with AAV5.5IDUA vector (n = 4), 
MPSI dogs treated with AAV2.5IDUA vector (n = 10), MPSIIIB dogs treated with 
AAV2.5NaGlu vector (n = 7). Data are means ± SEM and not significantly different 
between groups. Equivalent proportions indicate equivalent spreading of the 
different vectors used in this study in dog brain. (b) Mean ± SEM of the proportion of 
fragments in which >0.1 vector genome copy/cell was measured in MPSI dogs 
treated with AAV2.5IDUA vector before 5.2 months (D23, D29, D30, D31, D33, D37) 
or after 7.3 months (D15, D16, D17, D25) of age. Data are not significantly different 
between groups. AAV, adeno-associated virus; IDUA, α-iduronidase; MPSIII, 
mucopolysaccharidosis type III; NAGLU, α-N-acetylglucosaminidase. 
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Figure2.  
Improvement of disease markers in treated dog brains. Biochemical and histological 
markers of disease severity in the brain were measured in untreated normal dogs (n 
= 5), untreated MPSI dogs (n = 5), MPSI dogs treated with AAV5.5IDUA vector (n = 
4), MPSI dogs treated with AAV2.5IDUA vector (n = 10), untreated MPSIIIB dogs (n 
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= 3), and MPSIIIB dogs treated with AAV2.5NaGlu vector (n = 7). All treated dogs 
received immunosuppressants (data from B54 and B89, which were not fully 
immunosuppressed, are not included). (a–c) Biochemical markers. (a) GAG, (b) 
GM2, and (c) GM3 amounts were measured in brain extracts. Four values 
corresponding to four brain regions were determined in each dog. Data are means ± 
SEM of all determined values in each dog group. (d,e) Histological markers. Brain 
coronal slabs were processed for 4-µm paraffin sections. (d) Sections from the 
frontal cortex, the occipital cortex, the thalamus, or the caudate nucleus were 
stained with hematoxylin–eosin. Cell vacuolation was scored semiquantitatively from 
zero to three for each of these four regions in each dog, zero indicating absence of 
observed storage lesions, 1 up to 20% of affected cells, 2 up to 50%, 3 >50% 
(scores of individual animals at each location are shown in Figure 3). A global score 
represented by the mean of the four values was attributed to each dog. Histograms 
indicate means ± SEM of global scores in each dog group. (e) Sections of the 
caudate nucleus were stained with luxol fast blue, which stains storage lesions in 
blue. The total number of luxol fast blue positive lesions was scored in a surface of 
10.45 ± 0.47 mm2 covering a region located between the internal capsule to the 
brain surface. Data are means ± SEM of values determined in each dog group. 
Asterisks indicate significant differences between groups (P < 0.05, Mann and 
Whitney test). AAV, adeno-associated virus; GAG, glycosaminoglycan; IDUA, α-
iduronidase; MPSIII, mucopolysaccharidosis type III; NAGLU, α-N-
acetylglucosaminidase. 
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Figure3.  
Reduction of cell vacuolation in treated dog brains. Brain coronal slabs were 
processed for 4-µm paraffin sections. Sections were stained with hematoxylin–eosin 
and cell vacuolation was scored semiquantitatively from zero to three in the frontal 
cortex, the occipital cortex, the thalamus and the caudate nucleus (1: up to 20% of 
affected cells; 2: up to 50%; 3: >50%). (a) Examples of frontal cortex sections scored 
1 or 3 in treated (D30) or untreated (D14) MPSI dog, respectively, and in treated 
(B18) or untreated (B98) MPSIIIB dogs, respectively. (b) A color code indicates 
scores at each location for each treated or untreated dog examined in this study. A 
global score represented by the mean of the four determined scores is shown on the 
right (mean score). This score is used in Table 1 and Figure 2d. All treated dogs 
received immunosuppressant except B54, which did not receive 
immunosuppressant, and B89, in which immunosuppressant was halted two months 
before analysis. AAV, adeno-associated virus; MPSIII, mucopolysaccharidosis type 
III. 
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Figure 4.  
Residual lesions in dog brains. Four-micrometer paraffin sections of the caudate 
nucleus were stained with silver impregnation and luxol fast blue, which reveals 
intracytoplasmic accumulation of glycosaminoglycans and gangliosides. Luxol fast 
blue positive accumulation is visible in untreated MPSIIIB (D98) and MPSI (D14) 
dogs (left column), as well as in B54, a MPSIIIB dogs that did not receive 
immunosuppressant (middle, upper row) and in D17, a MPSI dog that was treated at 
the age of 10.0 months (right, bottom row). In contrast, luxol fast blue positive 
staining is not visible in B18, a MPSIIIB treated dog that received 
immunosuppressant (right, upper row) and D30, a MPSI dog that was treated at the 
age of 4.1 months (bottom, middle row). Bar = 50 µm. AAV, adeno-associated virus; 
IDUA, α-iduronidase; IS, immunosuppression; MPSIII, mucopolysaccharidosis type 
III; NAGLU, α-N-acetylglucosaminidase. 
 
 
 
 
 
